Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Suppression of Cornea Stromal Fibrosis by Vitamin D

Source: Article title. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Mixed research settings

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This study investigated the antifibrotic role of 1,25-dihydroxyvitamin D3 (1,25 Vit D) and the lesser-known vitamin D, 24,25-dihydroxyvitamin D3 (24,25 Vit D), in human and mouse corneal stromal cells (HSCs and MSCs) and in a Vit D receptor knockout (VDR KO) mouse model.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Suppression of Cornea Stromal Fibrosis by Vitamin D

Study design awaiting verification · Cells · 2025

Original publication title

Suppression of Cornea Stromal Fibrosis by Vitamin D

Xiaowen Lu; Zhong Chen; Jerry Lu; Mitchell A. Watsky

© 2025 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Our group has previously demonstrated the positive influence of Vit D on corneal epithelial cells and its involvement in corneal wound healing. The current study focused on the influence of Vit D on corneal keratocyte wound responses. We demonstrated that VDR KO resulted in increased NaOH-induced corneal fibrosis. Conversely, exposure of cultured stromal cells and mouse corneas to Vit D metabolites (1,25 Vit D and 24,25 Vit D) significantly decreased expression of α-SMA, a hallmark of myofibroblast phenotype. Furthermore, both 1,25 Vit D and 24,25 Vit D significantly increased the expression of key TGF-β superfamily antifibrotic factors BMP2, BMP6, BMPR2, and TGF-β3 at both the mRNA and protein levels in human stromal cells.

These findings highlight the robust antifibrotic potential of Vit D metabolites through modulation of critical signaling pathways. While both metabolites suppress fibrosis, 24,25 Vit D operates primarily through the newly identified receptor FAM57B (detected in all corneal layers), whereas 1,25 Vit D likely acts via VDR and PDIA3. 24,25 Vit D uniquely enhances BMP6/TGF-β3 signaling without VDR dependence, suggesting non-overlapping therapeutic targets.

Additionally, our results demonstrate that VDR plays a crucial role in immune cell recruitment during corneal wound healing. Specifically, VDR KO mouse corneas exhibited significantly reduced CD45+ immune cell infiltration following alkali injury compared to WT controls. Given the essential functions of CD45+ immune cells, including modulation of inflammation, clearance of debris and pathogens, secretion of cytokines and growth factors, and regulation of keratocyte activation, this impaired recruitment in VDR KO mice likely contributes to increased corneal fibrosis.

In summary, our findings support the beneficial role of Vit D and its receptor across multiple phases of corneal wound healing. Through the likely reduction of myofibroblast differentiation and enhancement of antifibrotic signaling through BMPs and TGF-β3 pathways, Vit D metabolites represent promising therapeutic agents for reducing corneal fibrosis after injury or surgery. The broader implications of this study along with our previous work demonstrating the beneficial effects of Vit D on corneal epithelial wound healing, including topical application of 1,25 and 24,25 Vit D, suggest potential clinical applications for topical Vit D analogs in treating ocular surface disorders characterized by fibrosis and impaired wound healing.

Although this study lacks in vivo topical or systemic Vit D treatment: an area that should be prioritized in future fibrotic wound healing research: there is strong rationale to pursue such work. Given the beneficial aspects of Vit D for many aspects of corneal wound healing and physiology, future studies should test metabolite-specific Vit D formulations (e.g., 24,25 Vit D for VDR-independent action) for their anti-fibrosis and beneficial wound healing properties following corneal injuries.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Corneal opacity, which can occur following trauma, chemical injury, infection, or surgery, is a leading cause of vision loss; thus, enhancing treatments that promote the resolution of stromal fibrosis-induced corneal scarring is crucial [1]. The pathophysiologic process of corneal fibrosis/scarring involves differentiation of corneal keratocytes into fibroblasts and myofibroblasts, which leads to the deposition of disorganized collagen fibrils and extracellular matrix (ECM) [2]. Vitamin D (Vit D), a multifunctional hormone that plays an essential role in calcium homeostasis, immune system regulation and cell differentiation, has been shown to modulate liver fibrosis, lung fibrosis, and cutaneous scar formation [3,4,5,6,7,8].

These modulating roles in fibrosis suggest that Vit D may be able to reduce stromal fibrosis-induced scarring and resolve corneal haze, alluding to future potential therapeutic applications in ocular surgeries.

The keratocyte-to-myofibroblast transition plays a central role in corneal fibrosis [9,10,11]. Antifibrotic factors, which maintain corneal transparency by regulating fibrotic events, are essential for corneal wound healing. By reducing inflammation and promoting ordered stromal regeneration, these factors support proper repair and restore corneal clarity after injury or surgery. TGF-β superfamily bone morphogenetic proteins, including BMP2, BMP6 and TGF-β3, are established antifibrotic factors in the cornea, effectively reducing collagen deposition, strongly modulating fibroblast activity, and potently suppressing myofibroblast differentiation [12,13].

BMP signaling occurs primarily through bone morphogenetic protein receptor type 2 (BMPR2), a critical receptor that enhances cellular responsiveness to BMPs [12]. Signaling events at BMPR2 robustly inhibit fibrosis by counteracting pro-fibrotic TGF-β-driven responses and promoting antifibrotic gene expression. Thus, BMPR2-mediated BMP signaling is highly effective in suppressing collagen deposition, regulating fibroblast behavior, and potently inhibiting myofibroblast differentiation.

Many tissues in the eye can both activate and respond to Vit D [14] and Vit D deficiency has been associated with a wide range of ocular pathologies, including myopia [15], age-related macular degeneration [16,17], diabetic retinopathy [18], uveitis [19], and glaucoma [20]. Previous studies have shown that Vit D may play a protective role in ocular health [21]. These roles include inhibition of angiogenesis in transgenic murine retinoblastoma [22], inhibition of corneal neovascularization induced by sutures [23] and retinal neovascularization in murine eyes [24], prevention of retinal autoimmune disease and mitigation of uveitis [25], and decreased retinal inflammation and levels of amyloid beta accumulation [26], as well as lowering intraocular pressure in primates [27].

1,25-dihydroxyvitamin D3 (1,25 Vit D), the long recognized active Vit D metabolite, has been found to induce keratinocyte differentiation and proliferation in skin [28]. It also regulates ECM turnover and mediates matrix metalloproteinase (MMP) production, including MMP-2 and MMP-3, during cell maturation and hypertrophy [29]. 1,25 Vit D was also found to significantly reduce the expression levels of α-smooth muscle actin (α-SMA) and fibronectin in a dose-dependent manner in TGF β1-induced fibroblasts derived from nasal polyps [30].

In the Vit D metabolic pathway, both 25-hydroxyvitamin D3 and 1,25 Vit D can be metabolized by 24-hydoxylase to form 24,25-dihydroxyvitamin D3 (24,25 Vit D). It has only recently been recognized that 24,25 Vit D is more than a metabolic byproduct of Vit D metabolism, as 24,25 Vit D injections have been shown to restore callus volume, stiffness, and mineralized cartilage area in cytochrome P450 family 24 subfamily A member 1 null mice [31]. Our group previously identified that 24,25 Vit D is a prevalent Vit D metabolite in the rabbit eye and demonstrated that 24,25 Vit D enhances corneal epithelial cell proliferation and enhances gap junction communication [32,33].

We also described significant effects of 1,25 Vit D and 24,25 Vit D in VDR KO corneal epithelial cells, and attributed those findings to the presence of alternative Vit D receptors in these cells [32,33]. The current study examines the hypothesis that 1,25 Vit D and 24,25 Vit D can alter the progression of fibrosis following wound healing. To the best of our knowledge, this is the first study to examine the possible antifibrotic effects of 24,25 Vit D.

Along the same line, this study also examines alternative Vit D receptors in keratocytes, which also have not been studied regarding their anti-fibrotic properties.

FAM57B has recently emerged as a putative receptor for 24,25 Vit D, providing new insight into noncanonical Vit D signaling pathways. Specifically, studies revealed that 24,25 Vit D binds to FAM57B2, triggering lactosylceramide production, which is essential for cartilage maturation and callus formation [31]. In the context of corneal injury, where VDR expression may be altered or absent, FAM57B-mediated signaling could represent a compensatory or complementary pathway by which 24,25 Vit D exerts protective, antifibrotic effects.

Elucidating the functional role of FAM57B in this setting could significantly expand our understanding of vitamin D biology and its therapeutic potential in ocular and fibrotic diseases.

Resident immune cells in the corneal epithelium and stroma include dendritic cells, macrophages, mast cells, and innate lymphoid cells [34,35]. Following corneal epithelial debridement in mice, large numbers of CD45+ cells infiltrate the stroma, including monocytes, macrophages, neutrophils, lymphocytes, and stem cells [36,37,38]. These infiltrating CD45+ cells play critical roles in the wound healing process by modulating inflammation, clearing cellular debris and pathogens, secreting cytokines and growth factors, and influencing keratocyte activation and differentiation [39].

A recent study from our group found that CD45+ cells with dendriform morphology were significantly reduced in the basal epithelial layer of wounded diabetic mouse corneas compared to normoglycemic mice, with topical 24,25 Vit D increasing their numbers [40].

Although Vit D metabolites (1,25 Vit D and 24,25 Vit D) demonstrate antifibrotic effects in extraocular tissues through VDR-SMAD3 inhibition and BMP-SMAD1/5 activation [41,42,43], their role in corneal TGF-β/BMP signaling remains uncharacterized. Crucially, FAM57B, a receptor for 24,25 Vit D, is detectable in osteoblasts and chondrocytes [31] but unstudied in corneal cells. This study tests the hypothesis that 1,25 Vit D and 24,25 Vit D attenuate corneal myofibroblast differentiation via VDR-dependent and FAM57B-mediated pathways, respectively, by modulating BMP/TGF-β3 expression and immune cell recruitment.

We explored the effects of Vit D on the corneal stroma, specifically examining the role of Vit D metabolites in corneal keratocyte to myofibroblast transition and corneal fibrosis after wounding.

Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction Source: 1. Introduction

Study methods

What methods does the paper describe?

2.1. Experimental Design

This study used a multi-method approach to test the hypothesis that Vit D can influence corneal wound healing and fibrosis, as well as the transition of keratocyte to myofibroblast. Cell culture studies were performed in a controlled environment to compare results between human and mouse stromal cells. Organ culture was utilized to move those studies from cells to whole corneas. In vivo studies were performed to determine if VDR KO influences immune cell infiltration and fibrotic wound healing in the live animal, an environment impossible to mimic in vitro.

2.2. Materials

The following reagents were procured from their respective suppliers: 1,25 Vit D and 24,25 Vit D were sourced from Enzo Life Sciences (#BML-DM200-0050, BML-DM300-0050, Farmingdale, NY, USA). Primary antibodies included anti-α-SMA monoclonal antibody, anti-CD45 polyclonal antibody, and anti-BMP6 monoclonal antibody (ABCAM, #ab32575, ab10558, and ab155963, Waltham, MA, USA), anti-type III Collagen-UNLB (SouthernBiotech, #1330-01, Birmingham, AL, USA), anti-fibronectin (Millipore sigma, #6140, St. Louis, MO, USA), anti-FAM57B2 (used in the recent J. Clin. Invest. study to identify this protein as a 24,25 Vit D receptor [31]; Biorbyt, #orb183613, Durham, NC, USA), and anti-TGF β3 polyclonal antibody (ThermoFisher Scientific, #PA5-32630, Waltham, MA, USA).

Secondary antibodies included goat anti-rabbit IgG (H + L) Alexa Fluor 488, donkey anti-Goat IgG (H + L) Alexa Fluor™ 555, goat anti-Mouse IgG (H + L) Alexa Fluor™ 633, and peroxidase-conjugated anti-rabbit IgG secondary antibody (ThermoFisher Scientific, #A-11034, #A-21432, #A-21052, #31460).

2.3. Animal Experiments

VDR knockout (VDR KO) mice were obtained from The Jackson Laboratory (B6.129S4-Vdrtm1Mbd/J Strain #: 006133). Wild type (WT) littermates were used as controls for all studies. All animal procedures were approved by the Augusta University Institutional Animal Care and Use Committee (protocol number: 2013-0581) and adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Visual Research (https://integration.arvo.org/About/policies/statement-for-the-use-of-animals-in-ophthalmic-and-vision-research/ accessed on 21 April 2025). The animals were housed under standard conditions with a 12-h dark-light cycle. At the conclusion of the experiments, mice were euthanized by CO2 inhalation followed by cervical dislocation.

2.4. Cornea Fibroblast Cell Culture

Primary human and mouse cornea stromal cells and a human cornea stroma cell line were used for this study. Primary human stromal cells were obtained from multiple donors (males ages 32 yr, 33 yr, 58 yr). The stromal cell line has been previously described [44,45], and the isolation and culturing methods for the human and mouse primary cornea stromal fibroblasts (HSCs and MSCs) have been described in detail [46]. Briefly, donor human cornea rims and mouse corneas from four 4-week-old WT and VDR KO C57BL/6 mice were minced with scissors and placed in DMEM (ThermoFisher Scientific, #11965118) plus 1% fetal bovine serum (ThermoFisher Scientific, #SH3007103HI), and incubated at 37 °C with 5% CO2, allowing for migration of the cells out of the tissue and onto an uncoated culture dish.

To confirm the keratocyte lineage, cells were routinely screened using western blotting for the corneal stromal cell-specific marker keratocan and the fibroblast marker Thy1/CD90 [47,48]. Primary mouse cornea stromal cells were from 6 mice. For all cell culture experiments, cell passages 2 to 6 were used.

Use of de-identified human donor cornea rims was deemed exempt by the Augusta University IRB committee. All protocols for animal use and euthanasia were reviewed and approved by the Augusta University Institutional Animal Care and Use Committee and followed the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

2.5. Corneal Fibroblast Vit D Treatment

MSCs and human stroma cell line HSCs were treated with 1,25 Vit D (20 nM in DMSO) or 24,25 Vit D (100 nM in DMSO) and 10 ng/mL TGF β1 for 24 h (n = 5). We have found these concentrations and the 24-h time point to be effective in previous studies [49]. DMSO was administered to the control groups as the solvent control.

2.6. Antifibrotic Factor Expression in Primary HSCs Treated with Vit D

To investigate the effects of Vit D on antifibrotic factors (BMP2, BMP6, BMPR2, and TGFβ3), HSCs were treated with either 20 nM 1,25 Vit D or 100 nM 24,25 Vit D along with 10 ng/mL TGF β. RNA was extracted from the cells using TRIzol (ThermoFisher Scientific, #15596026) at 2-, 6-, and 12-h post-treatment to assess gene expression. Q-PCR was performed to analyze gene expression levels using three biological replicates for each condition. Gene expression levels in the treated group were normalized to those in the control group.

Each sample was analyzed using technical triplicates to ensure accuracy and reproducibility. For antifibrotic factor protein expression analysis, the cells were collected at 24 h (n = 3).

2.7. Protein Extraction and Western Blot Analysis

HSCs as well as WT and VDR KO MSCs were cultured in uncoated 35-mm dishes. The cultured cells were washed with ice-cold PBS and treated with lysis buffer (Cell Signaling Technology, Catalog# 2881S, Danvers, MA, USA) for protein extraction. Following established protocols, cell lysates were collected and analyzed via western blotting, with subsequent quantification utilizing total protein measurements as previously described [32,50]. Briefly, protein samples were prepared and subjected to SDS-PAGE on Stain-free Gels with a 4 to 15% gradient (Bio-Rad, #4568084, Hercules, CA, USA).

The separated proteins were transferred onto PVDF membranes (Bio-Rad #1704272). Subsequently, the membranes were incubated overnight at 4 °C with the α-SMA (1:3000), BMP6 (1:1000), and TGFβ3 (1:1000) primary antibodies diluted in TBST containing 10% non-fat milk. Following primary antibody incubation, membranes were treated with the peroxidase-conjugated anti-rabbit IgG secondary antibody diluted 1:5000 in TBST with 10% non-fat dry milk for 1 h. Detection and quantification of band intensities were performed using Image Lab 5.2.1 software in conjunction with ChemiDoc MP (Bio-Rad) [51].

Band intensities were normalized to total protein by calculating the ratio of each band’s intensity to the total protein intensity from the corresponding sample on the same blot.

2.8. Immunofluorescence Studies

Mouse eyes enucleated from euthanized mice were flash-frozen in liquid nitrogen, embedded in Tissue-Tek optimal cutting temperature (OCT) compound (Electron Microscopy Sciences, Hatfield, PA, USA), and cryosectioned for immunohistochemistry. 10 μm-thick Cryosections were fixed in 4% paraformaldehyde for 10 min and then blocked with 10% goat serum in 0.1% Triton X-100/PBS for 1 h at room temperature. Cryosections were incubated overnight at 4 °C with primary antibodies, including anti-α-SMA, anti-collagen III, anti-fibronectin, anti-FAM57B2, and anti-CD45, and diluted 1:200 in block solution.

After washing with PBS three times for 10 min each, cryosections were incubated with goat anti-rabbit IgG (H + L) Alexa Fluor 488, donkey anti-Goat IgG (H + L) Alexa Fluor™ 555, goat anti-Mouse IgG (H + L) Alexa Fluor™ 633 secondary antibody at a dilution of 1:800 for 1 h and washed thoroughly with PBS. Examination of cryosections was performed using a Zeiss LSM 780 inverted laser-scanning confocal microscope (Zeiss Microscopy, Jena, Germany). Sections from 3 control and 3 treated corneas were examined.

For cultured human and mouse fibroblasts, cells were cultured in 24-well cell culture plates with glass coverslips. The immunofluorescence protocol was the same as for the cryosections with three biological replicates included for each experimental group. Secondary antibody negative controls were examined in all immunostaining experiments.

The expression levels of α-SMA, fibronectin, and collagen III were quantified by scoring fluorescence intensity throughout the corneal stromal layer in mouse corneal frozen section samples. For each experimental group: NaOH wounded WT, NaOH wounded VDR KO and unwounded WT mice: six frozen sections were analyzed, representing three corneas from three mice. Fluorescence scoring was performed independently by a qualified observer in a blinded manner. A modified Allred scoring system was applied, in which relative expression was classified as 0 (Low), 1 (Mid-Low), 2 (High-Mid), or 3 (High) based on the distribution and staining intensity of the biomarker of interest [52,53].

Statistical analysis of biomarker scores was performed using an unpaired t-test in GraphPad Prism (version 10.5.0, GraphPad Software, San Diego, CA, USA)

2.9. Mouse Cornea Organ Culture

To examine the effect of Vit D on mouse cornea TGF β1-stimulated α-SMA expression, mouse corneas were placed in a culture dish in DMEM serum-free medium for a total 48 h and treated with TGF β1 (10 ng/mL) only, TGF β1 plus 1,25 Vit D (20 nM) or 24,25 Vit D (100 nM) (n = 5). Mouse corneas were incubated at 37 °C with 5% CO2. Total protein was prepared from corneal tissue using protein lysis buffer.

2.10. Real Time PCR

Total RNA was extracted from HSCs treated with TGF β1 plus 1,25 Vit D (20 nM) or 24,25 Vit D (100 nM) using the TRIzol protocol (ThermoFisher Scientific, # 15596026). Real time PCR was used to quantify TGFβ3, BMP2, BMP6, and BMPR2 mRNA levels. RPS19BP1was used as the internal RNA control. RT-PCR primers were generated from the PrimerBank database using National Center for Biotechnology Information (NCBI) sequence identification numbers (NM_003239.4, NM_001200.4, NM_001718, NM_001204.5, NM_194326.2 for TGF β3, BMP2, BMP6, BMPR2, and RPS19BP1, respectively).

Primer sequences are listed in Table 1. mRNA was isolated and cDNA was synthesized using the Bio-Rad RT-PCR system. First-strand synthesis was performed at 42 °C for 60 min and inactivated at 85 °C for 5 min. cDNA was used for PCR amplification in triplicate using SYBR probes on the Bio-Rad system. Amplification was carried out at 95 °C for 10 min, followed by 40 cycles at 95 °C for 10 s and 60 °C for 30 s. Quantitative values were determined from the quantification cycle (Cq), and each sample was normalized using ∆Cq.

The results were analyzed with the 2(∆∆Cq) method. Bio-Rad CFX Manager 3.1 software was used for RT-PCR data analysis.

2.11. Effects of VDR KO on Corneal Transparency and Recruitment of Immune Cells in NaOH Wounded Mice

To determine how VDR KO effects mouse corneal transparency following an alkali wound, wild-type (WT) C57BL/6J VDR KO mice (n = 5 per group) between 8 and 9 weeks old were anaesthetized with ketamine: xylazine. A central cornea injury was created by placing a 0.33 N NaOH soaked filter paper disc (2 mm diameter) on the central cornea for 10 s. Corneas were rinsed with 10 mL PBS and treated with topical antibiotic ointment 2 times per day for 3 days.

Mice were treated with buprenorphine SR as an analgesic. Mouse corneal transparency was observed and photographed up to 21 days after wounding using a Topcon slit lamp (SL-D4).

To determine the effects of VDR KO on immune cell recruitment, wounded and control mouse corneas were collected 3 weeks after NaOH wounding (n = 5 per group) and immunostained with an anti-CD45 antibody. Briefly, mouse eyes were fixed in Zamboni fixative for 75 min and washed three times with PBS (5 min each). Corneas were excised along the sclera-corneal border, rehydrated in Triton X-100/PBS, and blocked with 10% goat serum and 0.1% Triton X-100 in PBS for 60 min at room temperature.

They were then incubated with anti-CD45 antibody (1:200, Abcam) in 5% goat serum and 0.1% Triton X-100/PBS for 24 h at 4 °C with constant shaking. After three 10-min PBS washes, corneas were treated with Alexa Fluor 594 goat anti-rabbit IgG (1:1000) for 24 h at 4 °C and thoroughly washed in PBS. To image the corneas, each was flattened by making four radial cuts and mounted on a slide with the epithelium side facing up. CD45+ cell numbers were quantified using the Imaris Spots package (Oxford Instruments, Abingdon, UK).

This 3D/4D visualization software effectively counts individual cells in 2D images. By inputting a 2D image and calibrating the Spots function: selecting the average cell diameter and setting initial sensitivity: the software labels cells as spots and reports the total count. A conservative approach was used to manually adjust counts, ensuring only clear cells (spots) in saturated areas were included [40].

2.12. Statistical Analysis

Data comparisons between two groups were conducted using an unpaired Student’s t-test. One-way ANOVA with Dunnett’s multiple comparison test was used when there was more the 1 experimental group. Statistical significance was determined based on a p-value of less than 0.05. Data analysis was performed using Graph Pad Prism 10.

Table 1

Summary of primer pair sets.

GeneDirectionPrimer SequenceProduct Size (bp)Melting
Temperature
Homo sapiens TGFβ3 Forward5′-AAGAAGCGGGCTTTGGAC-3′6260 °C
Reverse5′-CGCACACAGCAGTTCTCC-3′
Homo sapiens BMP2 Forward5′-CCCAGCGTGAAAAGAGAGAC-3′16861 °C
Reverse5′-GAGACCGCAGTCCGTCTAAG-3′
Homo sapiens BMP6 Forward5′-AGCGACACCACAAAGAGTTCA-3′15962 °C
Reverse5′-GCTGATGCTCCTGTAAGACTTGA-3′
Homo sapiens RPS19BP1Forward5′-CGTGGCTGAGTCTGTGAGC-3′12060 °C
Reverse5′-GTCTTCCTCGGTGAACACG-3′
Homo sapiens BMPRForward5′-CTTTACTGAGAATTTTCCACCTCCTG-3′9059 °C
Reverse5′-GCCAAAGCAATGATTAT TGTCTCATC-3′
Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods Source: 2. Materials and Methods

Effect of Vit D on α-SMA Protein Expression in the Human Stromal Cell Line and Primary HSC Cells

Results: Effect of Vit D on α-SMA Protein Expression in the Human Stromal Cell Line and Primary HSC Cells

TGF β1-stimulated α-SMA protein expression was significantly decreased after 72 h in the human stromal cell line and primary HSCs treated with 1,25 Vit D or 24,25 Vit D (Figure 1A: D, Supplementary Figure S1). 1,25 Vit D reduced TGF β1: stimulated α-SMA by 52.3% ± 4.1% (p < 0.001) in human stromal cells, while 24,25 Vit D reduced TGF β1: stimulated α-SMA by 48.7% ± 3.9% (p < 0.001) (Figure 1B,D). Figure 1E demonstrates decreased α-SMA immunostaining following 1,25 Vit D or 24,25 Vit D treatment in HSCs, highlighting the potential of Vit D metabolites to inhibit myofibroblast differentiation.

Source: 3.1. Effect of Vit D on α-SMA Protein Expression in the Human Stromal Cell Line and Primary HSC Cells

Effect of Vit D on α-SMA Protein Expression in Primary WT and VDR KO MSCs

Results: Effect of Vit D on α-SMA Protein Expression in Primary WT and VDR KO MSCs

TGF β1-stimulated α-SMA protein expression was decreased in cultured WT (Figure 2A,B) and VDR KO MSCs (Figure 2C,D, Supplementary Figure S2) 72 h after 1,25 Vit D or 24,25 Vit D exposure (p < 0.05). Unstimulated α-SMA protein expression was not significantly different between WT MSCs and VDR KO MSCs. Figure 2E demonstrates decreased α-SMA immunostaining following 1,25 Vit D or 24,25 Vit D treatment in MSCs.

Source: 3.2. Effect of Vit D on α-SMA Protein Expression in Primary WT and VDR KO MSCs

Effect of Vit D on TGF β1-Stimulated α-SMA Protein Expression in Mouse Corneas

Results: Effect of Vit D on TGF β1-Stimulated α-SMA Protein Expression in Mouse Corneas

Cultured mouse corneas were treated with TGF β1, with or without 1,25 Vit D or 24,25 Vit D, in DMEM serum-free medium. Figure 3 (and Supplementary Figure S3) shows significantly increased α-SMA protein expression in TGF β1-treated corneas compared to controls, and decreased α-SMA protein expression in mouse corneas treated with TGF β1 plus 1,25 Vit D or 24,25 Vit D.

Source: 3.3. Effect of Vit D on TGF β1-Stimulated α-SMA Protein Expression in Mouse Corneas

Results: Effect of VDR KO on Corneal Fibrosis

WT and VDR KO mouse corneas were injured using a 0.33N NaOH-soaked filter disc applied to the cornea for 10 s. Corneal healing/fibrosis was monitored with a slit lamp, with fluorescein staining utilized to examine epithelial healing. Epithelium of all eyes was healed by day 5; however, VDR KO mouse corneas exhibited more haze compared to WT corneas throughout the healing process. Figure 6A shows representative images of WT and VDR KO mouse corneas 14 days post-injury, with the VDR KO cornea displaying both a central epithelial defect and greater opacity. Figure 6B shows representative immunostaining for α-SMA, fibronectin, and collagen III in WT and VDR KO corneas, respectively, 14 days after alkali wounding, revealing increased expression of all three fibrotic marker proteins in the VDR KO versus WT corneas. Figure 6C shows the scoring results for each protein’s immunofluorescence.

Following wounding, WT corneas showed significantly increased α-SMA and fibronectin expression (p < 0.05) with no increase in collagen III expression. All three proteins were significantly increased in VDR KO corneas compared to unwounded WTs, with fibronectin and collagen III levels significantly increased in VDR KO compared to wounded WT corneas. The mean α-SMA score was elevated compared to wounded WTs but did not reach significance. In addition, the number of CD45+ immune cells was significantly reduced in VDR KO corneas compared to WT corneas three weeks post-wounding (Figure 7).

Specifically, wounded VDR KO corneas had 68% fewer CD45+ cells than WT post-injury (p < 0.001). This impaired immune recruitment likely potentiates fibrosis.

Source: 3.6. Effect of VDR KO on Corneal Fibrosis

Results: Localization of FAM57B in the Mouse Cornea

The FAM57B protein was recently described as a 24,25D receptor [31]. Immunohistochemical labeling of WT and KO mouse corneas revealed the presence of FAM57B in all 3 corneal cell types in both genotypes, with no discernable differences in labelling intensity (Figure 8).

Source: 3.7. Localization of FAM57B in the Mouse Cornea

Discussion

Vit D is well-known for its role in bone health and calcium metabolism. 1,25 Vit D is a central regulator of calcium and phosphate homeostasis and promotes cellular differentiation, stimulates apoptosis, and influences the proliferation of selected cell types. Vit D is also increasingly recognized for protective effects in head and neck tissues and cancers [54]. It modulates both innate and adaptive immunity by promoting antimicrobial peptides like cathelicidin and defensins [55]. Vitamin D also helps regulate autoimmune responses by suppressing pro-inflammatory T cells and enhancing regulatory T cells, with relevance to diseases like multiple sclerosis and rheumatoid arthritis [56].

Approximately 30 min of daily sun exposure without sunscreen is essential for the body’s natural production of vitamin D. During this process, UVB rays convert 7-dehydrocholesterol in the skin to vitamin D3, which is then hydroxylated in the liver and kidneys to form calcitriol [57].

Vitamin D plays a significant role in supporting ocular health. In the eye, vitamin D helps reduce cytokine production, oxidative stress, and microglial activation, thereby protecting against diseases such as age-related macular degeneration, dry eye syndrome, and diabetic retinopathy [14,58]. We previously determined that exposing cultured corneal epithelial cells to UV-B, in the presence of 7-dehydrocholesterol, resulted in a UV-B-dose dependent increase in vitamin D3, 1,25 Vit D and 24,25 Vit D. That same study determined that dietary vitamin D supplementation in rabbits resulted in elevated tear and anterior chamber 1,25 Vit D and 24,25 Vit D levels [58].

Vit D’s protective action is a cornerstone of numerous diseases, with Vit D deficiency-initiated oxidative stress being a significant contributor [59]. In cardiovascular tissues, VDR is expressed in fibroblasts, vascular endothelial cells, and cardiomyocytes, where vitamin D reduces renin: angiotensin system activity, enhances ACE2 expression, and lowers pro-inflammatory cytokines such as IL-1β and TNF-α [59]. Several studies have investigated the relationship between Vit D and fibrosis in different organs such as the liver, lungs, and heart [4,5,60,61].

Vit D can exert potent antifibrotic effects by attenuating NLRP3 assembly and reducing IL-1β release in both hepatic and cardiovascular tissue [59,62,63]. 1,25 Vit D was shown to prevent TGF β1-induced human cardiac fibroblast activation by inhibiting SMAD2 phosphorylation [60]. In the respiratory system, Vit D inhibits bleomycin and TGF β-induced pulmonary fibrosis [64,65]. The current study indicates that TGF β1-induced cornea myofibroblast differentiation, as determined by examining α-SMA expression, was reduced by 1,25 Vit D and 24,25 Vit D.

Importantly, it was also found that VDR KO led to more severe NaOH-induced corneal fibrosis as compared to WT mice. A more comprehensive assessment, including additional myofibroblast markers (such as fibronectin, collagen type III, and others), as well as broader transcriptional profiling, would provide a more robust evaluation of the myofibroblast differentiation process.

Wounded corneas from VDR KO mice exhibited significantly increased haze compared to those from WT mice, indicating enhanced fibrotic remodeling. Immunohistochemical analysis revealed elevated expression of key fibrotic markers in the wounded VDR KO corneas, including α-SMA, fibronectin, and collagen III. The trend of increased α-SMA expression suggests a greater presence of myofibroblasts. Similarly, increased fibronectin and collagen III deposition reflect heightened extracellular matrix production, further contributing to stromal disorganization and haze formation. These findings suggest that VDR signaling plays a critical regulatory role in limiting fibrotic responses during corneal wound healing.

Although the exact mechanisms are not fully understood, previous studies suggest that Vit D’s antifibrotic effects can be mediated by regulation of specific signaling pathways involved in fibrosis, modulation of the immune system, and its anti-inflammatory properties. Vit D metabolites may suppress TGF-β/Smad signaling. TGF β3 has been shown to be an antifibrotic agent in the cornea and several other tissues [66,67,68,69,70], possibly by upregulating SMAD7 in the cornea [71].

The current study demonstrates increased TGF β3 mRNA and protein expression in HSCs following exposure to both 1,25 Vit D and 24,25 Vit D; thus, it is possible that Vit D may reduce corneal fibrosis through the TGF β3 pathway.

Another group of TGF protein superfamily members with anti-fibrotic properties are the BMPs. A host of BMPs have been studied in the cornea, including BMP-2, -6, and -7, with each subtype being described as antifibrotic [12,13,72,73,74,75,76]. BMP-6 and BMPR2 have been reported to mediate phenotypic reversal of corneal myofibroblasts to keratocytes [77], and BMP-7 has been shown to attenuate corneal fibrosis [78,79,80].

Vit D and BMP-2 act synergistically to promote osteogenic differentiation, and PDIA3, a proposed alternative Vit D receptor, seems to be involved in this response [81,82]. The current study demonstrates increased HSC mRNA expression of BMP-2, -6, and BMPR2 (and BMP-6 protein) following 1,25 Vit D and 24,25 Vit D exposure. The influence of 24,25 Vit D on BMP signaling had not previously been reported in any cell type. The current study did not examine the possibility that the BMPs or TGF β3 were affected by TGF β1.

A separate study found that Vit D supplementation of Vit D-insufficient diabetic periodontitis patients resulted in elevated BMP-2 serum and gingival crevicular fluid samples [83]. Another study demonstrated increases of all 3 TGFβ isoforms following Vit D treatment of dermal fibroblasts [84]. In addition to BMP superfamily members, additional transcription factors and proteins that could be involved in Vit D antifibrotic activity include, but are not limited to, Snail, Slug, ZEB1, Twist, S100A4, and MYH11. To the best of our knowledge, the influence of Vit D on expression of these transcription factors and proteins has not previously been examined, and additional studies will be needed to determine how they are influenced by Vit D in the cornea.

Vitamin D upregulation of BMPs could potentially counteract TGF-β: induced fibrosis, as BMP-7 inhibits TGF β1: driven myofibroblast differentiation in renal and corneal models [85]. It would be beneficial for future studies to determine if Vit D metabolites directly modulate SMAD7 (an inhibitor of TGF-β signaling) or BMPR2 transcription.

It is well known that 1,25 Vit D works primarily through a VDR-mediated transcription mechanism in which the hormone directly regulates gene expression of a wide variety of Vit D-dependent genes in Vit D target cells. A recent study demonstrated that VDR ligands inhibit hepatic stellate cell activation and fibrosis, that VDR KO mice spontaneously develop liver fibrosis, and that VDR antagonizes SMAD3/TGF β1 activation of profibrotic genes [4]. Results of the current study determined that TGF β1-stimulated α-SMA protein expression was significantly reduced in both cultured WT and VDR KO MSCs following exposure to 1,25 Vit D or 24,25 Vit D.

Our group previously described significant physiological effects of 1,25 Vit D and 24,25 Vit D in VDR KO corneal epithelial cells, and attributed those findings to the presence of alternative Vit D receptors in these cells [32,33], and in particular the protein disulfide isomerase family member 3 (Pdia3), which has been identified as an alternative membrane-associated Vit D receptor [86]. To that end, we previously demonstrated Pdia3 expression in mouse and human corneal keratocytes [46].

Although its role beyond binding 24,25 Vit D is unexplored, we determined that a 24,25 Vit D receptor protein recently identified by St-Arnaud’s group, FAM57B2 [31], is also present in mouse corneal keratocytes as well as mouse corneal epithelial and endothelial cells. We attribute the current results observed in KO mouse MSCs to the presence of Pdia3, FAM57B2, or another alternative Vit D receptor in VDR KO MSCs. Future work could determine if FAM57B knockdown/knockout would abolish 24,25 Vit D’s antifibrotic effects.

It is important to compare results obtained from mouse and human studies, particularly when describing mouse models of human disease and developing or describing potential therapeutics. The current study found that TGF β1-induced corneal myofibroblast differentiation was significantly reduced by 1,25 Vit D and 24,25 Vit D in the human corneal stromal cell line, HSCs, MSCs, and cultured mouse corneas. These effects were confirmed in wounded mouse corneas. A previous study from our group in the corneal epithelium revealed species differences in Vit D metabolism and cell proliferation between humans and mice [46].

In cultured mouse corneal epithelium, 1,25 Vit D treatment increased CYP24A1, the enzyme responsible for inactivating 1,25 Vit D and forming 24,25 Vit D, decreased CYP27B1, the enzyme that activates Vit D, and did not affect proliferation. In human corneal epithelium, 1,25 Vit D also increased CYP24A1 expression but did not affect CYP27B1, and it reduced cell proliferation. In stromal cells of both species, 1,25 Vit D increased expression of both CYP24A1 and CYP27B1, highlighting species and cell type differences.

The differences suggest divergent metabolic regulation, impacting potential therapeutic dosing. Human corneal fibroblasts may require higher Vit D concentrations for efficacy due to catabolic differences. Topical formulations (e.g., nanocarriers) could overcome bioavailability issues [87]. A limitation of this study is that while multiple donors were used to obtain the human primary fibroblasts, the cells from individual donors were not tracked in the cell culture studies and all male donors were used. The relatively small variability in the results would indicate that there was not tremendous variability between donors.

It was surprising that the in vitro data demonstrated that both 1,25 Vit D and 24,25 Vit D suppressed α-SMA expression in TGF β1-induced stromal cells, even in the absence of VDR (indicating VDR-independent antifibrotic effects), while the in vivo results demonstrated exacerbated fibrosis in VDR KO mice after alkali injury compared to WT mice. There are several possible explanations for these seemingly contradictory results. While it might be expected that alternative receptors and endogenous 24,25 Vit D might compensate for loss of VDR in the KO mice, it is not known what concentration of 24,25D is reaching the cornea in these mice or what the density of alternative Vit D receptors might be within in vivo keratocytes.

In addition, the traditional VDR has a much higher affinity for 1,25 Vit D than other Vit D metabolites, thus it is likely that it would be difficult to overcome loss of VDR in an in vivo environment. While beyond the scope of this study, it would be interesting to determine if adding exogenous Vit D to in vivo KO mouse corneas would result in suppression of the observed fibrosis. These results also highlight the likely role of systemic and immune-mediated factors.

Specifically, the reduced infiltration of CD45+ immune cells in wounded VDR KO corneas suggests impaired immune modulation: a key regulator of fibrosis resolution that cannot be replicated in isolated cell cultures. Thus, the in vivo phenotype likely stems from compounded effects: compromised systemic immune responses due to VDR deficiency, in conjunction with cell-autonomous stromal signaling via alternative receptors like FAM57B. Future studies dissecting cell-type-specific contributions (e.g., stromal vs. immune cells) should help to further clarify these pathways.

Modulating immune responses and reducing inflammation are critical for corneal repair; for example, ocular microbiota has been found to play a role in maintaining corneal health [88]. Moreover, Vit D was found to improve wound healing and reduce IL6 production in Staphylococcus aureus-infected human keratinocytes [89]. CD45 is a marker for all hematopoietic cells except for mature erythrocytes and platelets. In the normal human and mouse cornea, there are a significant number of resident CD45+ cells within the pericentral and central region [37,90,91].

After a corneal scrape wound, neutrophils extravasate from the limbal vessels and migrate through the corneal stroma to the site of damage [92,93]. By 48 h, neutrophil levels within the stroma are near those found before injury [94]. Previous studies demonstrated that CD45+ immune cell immigration within wounded corneas occurs in two waves during the first 48 h [94]. Corneal re-epithelialization is significantly delayed in neutropenic animals, and early leukocyte emigration appears to promote re-epithelialization [95].

The current study found reduced numbers of CD45+ immune cells in VDR KO vs. WT corneas three weeks after NaOH wounding. In addition, our group recently determined that CD45+ cell numbers are reduced in diabetic and VDR KO mouse corneas compared to normoglycemic mice, and that 24,25 Vit D increased the recruitment of CD45+ cells to diabetic mouse corneas after epithelial debridement [40]. It was previously found that the VDR is required for recruitment of macrophages in cutaneous wounds, with the number of macrophages in granulation tissue markedly reduced in VDR KO compared with WT mice [96].

In addition, hepatic neutrophils are also decreased in VDR KO mice. Despite an increased awareness of the presence of corneal inflammatory cells in recent years, data demonstrating their precise role in normal corneal homeostasis is still rare [97]. Our findings suggest that Vit D and the VDR may play an important role in mitigating corneal fibrosis by modulating the immune system.

CD45+ cells have been shown to be both beneficial and detrimental as related to fibrosis. For example, CD45 cell therapy was found to be beneficial for treating CCl4-induced liver fibrosis [98], and CD45+ cells were found to alleviate bleomycin-induced pulmonary fibrosis by limiting expansion and activation of group 2 innate lymphoid cells [99]. Alternative examples include CD45+ fibrocytes promoting corneal injury-induced fibrosis [100], and CD45(+) cells correlated with mitral valve fibrosis following myocardial infarction [101].

The present study demonstrated reduced CD45+ cell infiltration following NaOH injury in VDR KO mouse corneas, which showed an enhanced fibrotic response, indicating a possible beneficial role for these cells in preventing or resolving chemical injury-induced fibrosis.

Additional limitations of the current study include an absence of VDR antagonists for validation of cell culture studies and in situ and in vivo studies that did not incorporate the VDR KO mice, limited time points and Vit D concentrations examined, and lack of in vivo functional assessments for some of the studies. It is noteworthy that we consider the 1,25 Vit D and 24,25 Vit D concentrations tested in the current study (20 nM and 100 nM, respectively) to be pharmacological doses and not physiological concentrations.

We previously determined that rabbit aqueous humor 1,25 Vit D and 24,25 Vit D levels to be as high as 0.04 nM and 0.27 nM, respectively (with no extra dietary Vit D supplementation) [58]. To the best of our knowledge, no studies have measured these Vit D metabolite concentrations in the eyes of humans or mice. We chose the higher 24,25 Vit D concentration (relative to the 1,25 Vit D concentration) due to its lower affinity for the VDR as compared to the high affinity agonist, 1,25 Vit D.

The affinity of 24,25 Vit D to the alternative receptors has not been thoroughly studied. Those Vit D concentrations examined in the current study were the same as those used in all of our previous cornea Vit D studies.

The current study indicates that 1,25 Vit D and 24,25 Vit D can be beneficial for reducing fibrotic wound healing following corneal alkali injuries. Previous work from our group demonstrated that Vit D promotes corneal epithelial wound healing. VDR KO mice have significantly slower cornea epithelial wound healing rates as compared to controls, and Vit D deficient diabetic mice have slower corneal epithelial wound healing than wild-type diabetic mice. Topical 1,25 Vit D significantly accelerated corneal epithelial wound healing in normoglycemic, diabetic, and diabetic VDD mice, and topical 24,25 Vit D significantly accelerated corneal epithelial wound healing of diabetic VDD and VDR KO mice [40].

We also found significant roles for Vit D in maintaining corneal epithelial adherens junctions, promoting gap junction communication, and affecting cell migration and proliferation. Thus, 1,25 Vit D and 24,25 Vit D appear to promote corneal wound healing following both mechanical and chemical wounding.

Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion Source: 4. Discussion

Results

3.1. Effect of Vit D on α-SMA Protein Expression in the Human Stromal Cell Line and Primary HSC Cells

TGF β1-stimulated α-SMA protein expression was significantly decreased after 72 h in the human stromal cell line and primary HSCs treated with 1,25 Vit D or 24,25 Vit D (Figure 1A: D, Supplementary Figure S1). 1,25 Vit D reduced TGF β1: stimulated α-SMA by 52.3% ± 4.1% (p < 0.001) in human stromal cells, while 24,25 Vit D reduced TGF β1: stimulated α-SMA by 48.7% ± 3.9% (p < 0.001) (Figure 1B,D). Figure 1E demonstrates decreased α-SMA immunostaining following 1,25 Vit D or 24,25 Vit D treatment in HSCs, highlighting the potential of Vit D metabolites to inhibit myofibroblast differentiation.

3.2. Effect of Vit D on α-SMA Protein Expression in Primary WT and VDR KO MSCs

TGF β1-stimulated α-SMA protein expression was decreased in cultured WT (Figure 2A,B) and VDR KO MSCs (Figure 2C,D, Supplementary Figure S2) 72 h after 1,25 Vit D or 24,25 Vit D exposure (p < 0.05). Unstimulated α-SMA protein expression was not significantly different between WT MSCs and VDR KO MSCs. Figure 2E demonstrates decreased α-SMA immunostaining following 1,25 Vit D or 24,25 Vit D treatment in MSCs.

3.3. Effect of Vit D on TGF β1-Stimulated α-SMA Protein Expression in Mouse Corneas

Cultured mouse corneas were treated with TGF β1, with or without 1,25 Vit D or 24,25 Vit D, in DMEM serum-free medium. Figure 3 (and Supplementary Figure S3) shows significantly increased α-SMA protein expression in TGF β1-treated corneas compared to controls, and decreased α-SMA protein expression in mouse corneas treated with TGF β1 plus 1,25 Vit D or 24,25 Vit D.

3.4. Effect of Vit D on Antifibrotic Protein Factor mRNA Expressional Levels in HSCs

TGF-β family members, including BMPs, are key regulators of tissue repair and fibrosis. BMP2 and BMP6 are notable antifibrotic factors, with BMP2 demonstrating the ability to inhibit fibrogenic signaling pathways and reduce collagen deposition in various tissues. Figure 4 shows qPCR results demonstrating the influence of Vit D on mRNA levels of several antifibrotic protein factors in HSCs. Results demonstrate that BMP2, 6, and BMPR2 mRNA, along with that of TGF β3, are significantly elevated by both 1,25 Vit D and 24,25 Vit D at most of the time points tested.

3.5. Effect of Vit D on BMP6 and TGF β3 Protein Expression in HSCs

Figure 5 (and Supplementary Figure S4) shows western blot data demonstrating increased HSC Vit D-stimulated protein levels of BMP6 (A,B) and TGF β3 (C,D), which were selected for protein measurement following the qPCR experiments. Treatment with 24,25 Vit D significantly increased both BMP6 and TGF-β3 protein levels compared with the control group. BMP6 expression showed an approximately 1.9 ± 0.3 fold elevation, while TGF-β3 expression increased by about 1.7 ± 0.2 fold. 1,25 Vit D also enhanced BMP6 and TGF-β3 expression, but to a slightly lesser extent. 1,25 Vit D-treated HSCs showed an approximately 1.7 ± 0.2 fold BMP6 increase, and TGF-β3 expression rose by roughly 1.6 ± 0.2 fold.

These results suggest that both active vitamin D metabolites upregulate BMP6 and TGF-β3.

3.6. Effect of VDR KO on Corneal Fibrosis

WT and VDR KO mouse corneas were injured using a 0.33N NaOH-soaked filter disc applied to the cornea for 10 s. Corneal healing/fibrosis was monitored with a slit lamp, with fluorescein staining utilized to examine epithelial healing. Epithelium of all eyes was healed by day 5; however, VDR KO mouse corneas exhibited more haze compared to WT corneas throughout the healing process. Figure 6A shows representative images of WT and VDR KO mouse corneas 14 days post-injury, with the VDR KO cornea displaying both a central epithelial defect and greater opacity. Figure 6B shows representative immunostaining for α-SMA, fibronectin, and collagen III in WT and VDR KO corneas, respectively, 14 days after alkali wounding, revealing increased expression of all three fibrotic marker proteins in the VDR KO versus WT corneas. Figure 6C shows the scoring results for each protein’s immunofluorescence.

Following wounding, WT corneas showed significantly increased α-SMA and fibronectin expression (p < 0.05) with no increase in collagen III expression. All three proteins were significantly increased in VDR KO corneas compared to unwounded WTs, with fibronectin and collagen III levels significantly increased in VDR KO compared to wounded WT corneas. The mean α-SMA score was elevated compared to wounded WTs but did not reach significance. In addition, the number of CD45+ immune cells was significantly reduced in VDR KO corneas compared to WT corneas three weeks post-wounding (Figure 7).

Specifically, wounded VDR KO corneas had 68% fewer CD45+ cells than WT post-injury (p < 0.001). This impaired immune recruitment likely potentiates fibrosis.

3.7. Localization of FAM57B in the Mouse Cornea

The FAM57B protein was recently described as a 24,25D receptor [31]. Immunohistochemical labeling of WT and KO mouse corneas revealed the presence of FAM57B in all 3 corneal cell types in both genotypes, with no discernable differences in labelling intensity (Figure 8).

Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results Source: 3. Results

Conclusions

Our group has previously demonstrated the positive influence of Vit D on corneal epithelial cells and its involvement in corneal wound healing. The current study focused on the influence of Vit D on corneal keratocyte wound responses. We demonstrated that VDR KO resulted in increased NaOH-induced corneal fibrosis. Conversely, exposure of cultured stromal cells and mouse corneas to Vit D metabolites (1,25 Vit D and 24,25 Vit D) significantly decreased expression of α-SMA, a hallmark of myofibroblast phenotype. Furthermore, both 1,25 Vit D and 24,25 Vit D significantly increased the expression of key TGF-β superfamily antifibrotic factors BMP2, BMP6, BMPR2, and TGF-β3 at both the mRNA and protein levels in human stromal cells.

These findings highlight the robust antifibrotic potential of Vit D metabolites through modulation of critical signaling pathways. While both metabolites suppress fibrosis, 24,25 Vit D operates primarily through the newly identified receptor FAM57B (detected in all corneal layers), whereas 1,25 Vit D likely acts via VDR and PDIA3. 24,25 Vit D uniquely enhances BMP6/TGF-β3 signaling without VDR dependence, suggesting non-overlapping therapeutic targets.

Additionally, our results demonstrate that VDR plays a crucial role in immune cell recruitment during corneal wound healing. Specifically, VDR KO mouse corneas exhibited significantly reduced CD45+ immune cell infiltration following alkali injury compared to WT controls. Given the essential functions of CD45+ immune cells, including modulation of inflammation, clearance of debris and pathogens, secretion of cytokines and growth factors, and regulation of keratocyte activation, this impaired recruitment in VDR KO mice likely contributes to increased corneal fibrosis.

In summary, our findings support the beneficial role of Vit D and its receptor across multiple phases of corneal wound healing. Through the likely reduction of myofibroblast differentiation and enhancement of antifibrotic signaling through BMPs and TGF-β3 pathways, Vit D metabolites represent promising therapeutic agents for reducing corneal fibrosis after injury or surgery. The broader implications of this study along with our previous work demonstrating the beneficial effects of Vit D on corneal epithelial wound healing, including topical application of 1,25 and 24,25 Vit D, suggest potential clinical applications for topical Vit D analogs in treating ocular surface disorders characterized by fibrosis and impaired wound healing.

Although this study lacks in vivo topical or systemic Vit D treatment: an area that should be prioritized in future fibrotic wound healing research: there is strong rationale to pursue such work. Given the beneficial aspects of Vit D for many aspects of corneal wound healing and physiology, future studies should test metabolite-specific Vit D formulations (e.g., 24,25 Vit D for VDR-independent action) for their anti-fibrosis and beneficial wound healing properties following corneal injuries.

Source: 5. Conclusions Source: 5. Conclusions Source: 5. Conclusions
Authors’ abstract

Corneal fibrosis, a significant source of visual impairment, can result from keratocyte-to-myofibroblast transdifferentiation during wound healing. This study investigated the antifibrotic role of 1,25-dihydroxyvitamin D3 (1,25 Vit D) and the lesser-known vitamin D, 24,25-dihydroxyvitamin D3 (24,25 Vit D), in human and mouse corneal stromal cells (HSCs and MSCs) and in a Vit D receptor knockout (VDR KO) mouse model. Cells were treated with TGF-β1 ± Vit D metabolites and the expression of fibrotic and antifibrotic genes and proteins was evaluated.

Both metabolites significantly reduced α-smooth muscle actin levels in HSCs, MSCs and organ-cultured mouse corneas (p < 0.05). They also upregulated the mRNA expression of BMP2, BMP6, BMPR2, and TGF-β3, as well as the protein expression of BMP6 and TGF-β3. VDR KO corneas subjected to alkali injury exhibited increased fibrotic responses and reduced CD45+ immune cell infiltration compared to wild-type controls. Notably, 24,25 Vit D exerted antifibrotic effects even in VDR KO cells, and the alternative 24,25 Vit D receptor FAM57B was expressed in all corneal cell layers.

These results reveal consistent antifibrotic effects of both 1,25 and 24,25 Vit D across species, support the existence of VDR-independent mechanisms in the cornea, and offer new insights into potential therapeutic strategies for preventing corneal fibrosis.

Read the full paper

1. Introduction

Corneal opacity, which can occur following trauma, chemical injury, infection, or surgery, is a leading cause of vision loss; thus, enhancing treatments that promote the resolution of stromal fibrosis-induced corneal scarring is crucial [1]. The pathophysiologic process of corneal fibrosis/scarring involves differentiation of corneal keratocytes into fibroblasts and myofibroblasts, which leads to the deposition of disorganized collagen fibrils and extracellular matrix (ECM) [2]. Vitamin D (Vit D), a multifunctional hormone that plays an essential role in calcium homeostasis, immune system regulation and cell differentiation, has been shown to modulate liver fibrosis, lung fibrosis, and cutaneous scar formation [3,4,5,6,7,8].

These modulating roles in fibrosis suggest that Vit D may be able to reduce stromal fibrosis-induced scarring and resolve corneal haze, alluding to future potential therapeutic applications in ocular surgeries.

The keratocyte-to-myofibroblast transition plays a central role in corneal fibrosis [9,10,11]. Antifibrotic factors, which maintain corneal transparency by regulating fibrotic events, are essential for corneal wound healing. By reducing inflammation and promoting ordered stromal regeneration, these factors support proper repair and restore corneal clarity after injury or surgery. TGF-β superfamily bone morphogenetic proteins, including BMP2, BMP6 and TGF-β3, are established antifibrotic factors in the cornea, effectively reducing collagen deposition, strongly modulating fibroblast activity, and potently suppressing myofibroblast differentiation [12,13].

BMP signaling occurs primarily through bone morphogenetic protein receptor type 2 (BMPR2), a critical receptor that enhances cellular responsiveness to BMPs [12]. Signaling events at BMPR2 robustly inhibit fibrosis by counteracting pro-fibrotic TGF-β-driven responses and promoting antifibrotic gene expression. Thus, BMPR2-mediated BMP signaling is highly effective in suppressing collagen deposition, regulating fibroblast behavior, and potently inhibiting myofibroblast differentiation.

Many tissues in the eye can both activate and respond to Vit D [14] and Vit D deficiency has been associated with a wide range of ocular pathologies, including myopia [15], age-related macular degeneration [16,17], diabetic retinopathy [18], uveitis [19], and glaucoma [20]. Previous studies have shown that Vit D may play a protective role in ocular health [21]. These roles include inhibition of angiogenesis in transgenic murine retinoblastoma [22], inhibition of corneal neovascularization induced by sutures [23] and retinal neovascularization in murine eyes [24], prevention of retinal autoimmune disease and mitigation of uveitis [25], and decreased retinal inflammation and levels of amyloid beta accumulation [26], as well as lowering intraocular pressure in primates [27].

1,25-dihydroxyvitamin D3 (1,25 Vit D), the long recognized active Vit D metabolite, has been found to induce keratinocyte differentiation and proliferation in skin [28]. It also regulates ECM turnover and mediates matrix metalloproteinase (MMP) production, including MMP-2 and MMP-3, during cell maturation and hypertrophy [29]. 1,25 Vit D was also found to significantly reduce the expression levels of α-smooth muscle actin (α-SMA) and fibronectin in a dose-dependent manner in TGF β1-induced fibroblasts derived from nasal polyps [30].

In the Vit D metabolic pathway, both 25-hydroxyvitamin D3 and 1,25 Vit D can be metabolized by 24-hydoxylase to form 24,25-dihydroxyvitamin D3 (24,25 Vit D). It has only recently been recognized that 24,25 Vit D is more than a metabolic byproduct of Vit D metabolism, as 24,25 Vit D injections have been shown to restore callus volume, stiffness, and mineralized cartilage area in cytochrome P450 family 24 subfamily A member 1 null mice [31]. Our group previously identified that 24,25 Vit D is a prevalent Vit D metabolite in the rabbit eye and demonstrated that 24,25 Vit D enhances corneal epithelial cell proliferation and enhances gap junction communication [32,33].

We also described significant effects of 1,25 Vit D and 24,25 Vit D in VDR KO corneal epithelial cells, and attributed those findings to the presence of alternative Vit D receptors in these cells [32,33]. The current study examines the hypothesis that 1,25 Vit D and 24,25 Vit D can alter the progression of fibrosis following wound healing. To the best of our knowledge, this is the first study to examine the possible antifibrotic effects of 24,25 Vit D.

Along the same line, this study also examines alternative Vit D receptors in keratocytes, which also have not been studied regarding their anti-fibrotic properties.

FAM57B has recently emerged as a putative receptor for 24,25 Vit D, providing new insight into noncanonical Vit D signaling pathways. Specifically, studies revealed that 24,25 Vit D binds to FAM57B2, triggering lactosylceramide production, which is essential for cartilage maturation and callus formation [31]. In the context of corneal injury, where VDR expression may be altered or absent, FAM57B-mediated signaling could represent a compensatory or complementary pathway by which 24,25 Vit D exerts protective, antifibrotic effects.

Elucidating the functional role of FAM57B in this setting could significantly expand our understanding of vitamin D biology and its therapeutic potential in ocular and fibrotic diseases.

Resident immune cells in the corneal epithelium and stroma include dendritic cells, macrophages, mast cells, and innate lymphoid cells [34,35]. Following corneal epithelial debridement in mice, large numbers of CD45+ cells infiltrate the stroma, including monocytes, macrophages, neutrophils, lymphocytes, and stem cells [36,37,38]. These infiltrating CD45+ cells play critical roles in the wound healing process by modulating inflammation, clearing cellular debris and pathogens, secreting cytokines and growth factors, and influencing keratocyte activation and differentiation [39].

A recent study from our group found that CD45+ cells with dendriform morphology were significantly reduced in the basal epithelial layer of wounded diabetic mouse corneas compared to normoglycemic mice, with topical 24,25 Vit D increasing their numbers [40].

Although Vit D metabolites (1,25 Vit D and 24,25 Vit D) demonstrate antifibrotic effects in extraocular tissues through VDR-SMAD3 inhibition and BMP-SMAD1/5 activation [41,42,43], their role in corneal TGF-β/BMP signaling remains uncharacterized. Crucially, FAM57B, a receptor for 24,25 Vit D, is detectable in osteoblasts and chondrocytes [31] but unstudied in corneal cells. This study tests the hypothesis that 1,25 Vit D and 24,25 Vit D attenuate corneal myofibroblast differentiation via VDR-dependent and FAM57B-mediated pathways, respectively, by modulating BMP/TGF-β3 expression and immune cell recruitment.

We explored the effects of Vit D on the corneal stroma, specifically examining the role of Vit D metabolites in corneal keratocyte to myofibroblast transition and corneal fibrosis after wounding.

2. Materials and Methods

2.1. Experimental Design

This study used a multi-method approach to test the hypothesis that Vit D can influence corneal wound healing and fibrosis, as well as the transition of keratocyte to myofibroblast. Cell culture studies were performed in a controlled environment to compare results between human and mouse stromal cells. Organ culture was utilized to move those studies from cells to whole corneas. In vivo studies were performed to determine if VDR KO influences immune cell infiltration and fibrotic wound healing in the live animal, an environment impossible to mimic in vitro.

2.2. Materials

The following reagents were procured from their respective suppliers: 1,25 Vit D and 24,25 Vit D were sourced from Enzo Life Sciences (#BML-DM200-0050, BML-DM300-0050, Farmingdale, NY, USA). Primary antibodies included anti-α-SMA monoclonal antibody, anti-CD45 polyclonal antibody, and anti-BMP6 monoclonal antibody (ABCAM, #ab32575, ab10558, and ab155963, Waltham, MA, USA), anti-type III Collagen-UNLB (SouthernBiotech, #1330-01, Birmingham, AL, USA), anti-fibronectin (Millipore sigma, #6140, St. Louis, MO, USA), anti-FAM57B2 (used in the recent J. Clin. Invest. study to identify this protein as a 24,25 Vit D receptor [31]; Biorbyt, #orb183613, Durham, NC, USA), and anti-TGF β3 polyclonal antibody (ThermoFisher Scientific, #PA5-32630, Waltham, MA, USA).

Secondary antibodies included goat anti-rabbit IgG (H + L) Alexa Fluor 488, donkey anti-Goat IgG (H + L) Alexa Fluor™ 555, goat anti-Mouse IgG (H + L) Alexa Fluor™ 633, and peroxidase-conjugated anti-rabbit IgG secondary antibody (ThermoFisher Scientific, #A-11034, #A-21432, #A-21052, #31460).

2.3. Animal Experiments

VDR knockout (VDR KO) mice were obtained from The Jackson Laboratory (B6.129S4-Vdrtm1Mbd/J Strain #: 006133). Wild type (WT) littermates were used as controls for all studies. All animal procedures were approved by the Augusta University Institutional Animal Care and Use Committee (protocol number: 2013-0581) and adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Visual Research (https://integration.arvo.org/About/policies/statement-for-the-use-of-animals-in-ophthalmic-and-vision-research/ accessed on 21 April 2025). The animals were housed under standard conditions with a 12-h dark-light cycle. At the conclusion of the experiments, mice were euthanized by CO2 inhalation followed by cervical dislocation.

2.4. Cornea Fibroblast Cell Culture

Primary human and mouse cornea stromal cells and a human cornea stroma cell line were used for this study. Primary human stromal cells were obtained from multiple donors (males ages 32 yr, 33 yr, 58 yr). The stromal cell line has been previously described [44,45], and the isolation and culturing methods for the human and mouse primary cornea stromal fibroblasts (HSCs and MSCs) have been described in detail [46]. Briefly, donor human cornea rims and mouse corneas from four 4-week-old WT and VDR KO C57BL/6 mice were minced with scissors and placed in DMEM (ThermoFisher Scientific, #11965118) plus 1% fetal bovine serum (ThermoFisher Scientific, #SH3007103HI), and incubated at 37 °C with 5% CO2, allowing for migration of the cells out of the tissue and onto an uncoated culture dish.

To confirm the keratocyte lineage, cells were routinely screened using western blotting for the corneal stromal cell-specific marker keratocan and the fibroblast marker Thy1/CD90 [47,48]. Primary mouse cornea stromal cells were from 6 mice. For all cell culture experiments, cell passages 2 to 6 were used.

Use of de-identified human donor cornea rims was deemed exempt by the Augusta University IRB committee. All protocols for animal use and euthanasia were reviewed and approved by the Augusta University Institutional Animal Care and Use Committee and followed the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

2.5. Corneal Fibroblast Vit D Treatment

MSCs and human stroma cell line HSCs were treated with 1,25 Vit D (20 nM in DMSO) or 24,25 Vit D (100 nM in DMSO) and 10 ng/mL TGF β1 for 24 h (n = 5). We have found these concentrations and the 24-h time point to be effective in previous studies [49]. DMSO was administered to the control groups as the solvent control.

2.6. Antifibrotic Factor Expression in Primary HSCs Treated with Vit D

To investigate the effects of Vit D on antifibrotic factors (BMP2, BMP6, BMPR2, and TGFβ3), HSCs were treated with either 20 nM 1,25 Vit D or 100 nM 24,25 Vit D along with 10 ng/mL TGF β. RNA was extracted from the cells using TRIzol (ThermoFisher Scientific, #15596026) at 2-, 6-, and 12-h post-treatment to assess gene expression. Q-PCR was performed to analyze gene expression levels using three biological replicates for each condition. Gene expression levels in the treated group were normalized to those in the control group.

Each sample was analyzed using technical triplicates to ensure accuracy and reproducibility. For antifibrotic factor protein expression analysis, the cells were collected at 24 h (n = 3).

2.7. Protein Extraction and Western Blot Analysis

HSCs as well as WT and VDR KO MSCs were cultured in uncoated 35-mm dishes. The cultured cells were washed with ice-cold PBS and treated with lysis buffer (Cell Signaling Technology, Catalog# 2881S, Danvers, MA, USA) for protein extraction. Following established protocols, cell lysates were collected and analyzed via western blotting, with subsequent quantification utilizing total protein measurements as previously described [32,50]. Briefly, protein samples were prepared and subjected to SDS-PAGE on Stain-free Gels with a 4 to 15% gradient (Bio-Rad, #4568084, Hercules, CA, USA).

The separated proteins were transferred onto PVDF membranes (Bio-Rad #1704272). Subsequently, the membranes were incubated overnight at 4 °C with the α-SMA (1:3000), BMP6 (1:1000), and TGFβ3 (1:1000) primary antibodies diluted in TBST containing 10% non-fat milk. Following primary antibody incubation, membranes were treated with the peroxidase-conjugated anti-rabbit IgG secondary antibody diluted 1:5000 in TBST with 10% non-fat dry milk for 1 h. Detection and quantification of band intensities were performed using Image Lab 5.2.1 software in conjunction with ChemiDoc MP (Bio-Rad) [51].

Band intensities were normalized to total protein by calculating the ratio of each band’s intensity to the total protein intensity from the corresponding sample on the same blot.

2.8. Immunofluorescence Studies

Mouse eyes enucleated from euthanized mice were flash-frozen in liquid nitrogen, embedded in Tissue-Tek optimal cutting temperature (OCT) compound (Electron Microscopy Sciences, Hatfield, PA, USA), and cryosectioned for immunohistochemistry. 10 μm-thick Cryosections were fixed in 4% paraformaldehyde for 10 min and then blocked with 10% goat serum in 0.1% Triton X-100/PBS for 1 h at room temperature. Cryosections were incubated overnight at 4 °C with primary antibodies, including anti-α-SMA, anti-collagen III, anti-fibronectin, anti-FAM57B2, and anti-CD45, and diluted 1:200 in block solution.

After washing with PBS three times for 10 min each, cryosections were incubated with goat anti-rabbit IgG (H + L) Alexa Fluor 488, donkey anti-Goat IgG (H + L) Alexa Fluor™ 555, goat anti-Mouse IgG (H + L) Alexa Fluor™ 633 secondary antibody at a dilution of 1:800 for 1 h and washed thoroughly with PBS. Examination of cryosections was performed using a Zeiss LSM 780 inverted laser-scanning confocal microscope (Zeiss Microscopy, Jena, Germany). Sections from 3 control and 3 treated corneas were examined.

For cultured human and mouse fibroblasts, cells were cultured in 24-well cell culture plates with glass coverslips. The immunofluorescence protocol was the same as for the cryosections with three biological replicates included for each experimental group. Secondary antibody negative controls were examined in all immunostaining experiments.

The expression levels of α-SMA, fibronectin, and collagen III were quantified by scoring fluorescence intensity throughout the corneal stromal layer in mouse corneal frozen section samples. For each experimental group: NaOH wounded WT, NaOH wounded VDR KO and unwounded WT mice: six frozen sections were analyzed, representing three corneas from three mice. Fluorescence scoring was performed independently by a qualified observer in a blinded manner. A modified Allred scoring system was applied, in which relative expression was classified as 0 (Low), 1 (Mid-Low), 2 (High-Mid), or 3 (High) based on the distribution and staining intensity of the biomarker of interest [52,53].

Statistical analysis of biomarker scores was performed using an unpaired t-test in GraphPad Prism (version 10.5.0, GraphPad Software, San Diego, CA, USA)

2.9. Mouse Cornea Organ Culture

To examine the effect of Vit D on mouse cornea TGF β1-stimulated α-SMA expression, mouse corneas were placed in a culture dish in DMEM serum-free medium for a total 48 h and treated with TGF β1 (10 ng/mL) only, TGF β1 plus 1,25 Vit D (20 nM) or 24,25 Vit D (100 nM) (n = 5). Mouse corneas were incubated at 37 °C with 5% CO2. Total protein was prepared from corneal tissue using protein lysis buffer.

2.10. Real Time PCR

Total RNA was extracted from HSCs treated with TGF β1 plus 1,25 Vit D (20 nM) or 24,25 Vit D (100 nM) using the TRIzol protocol (ThermoFisher Scientific, # 15596026). Real time PCR was used to quantify TGFβ3, BMP2, BMP6, and BMPR2 mRNA levels. RPS19BP1was used as the internal RNA control. RT-PCR primers were generated from the PrimerBank database using National Center for Biotechnology Information (NCBI) sequence identification numbers (NM_003239.4, NM_001200.4, NM_001718, NM_001204.5, NM_194326.2 for TGF β3, BMP2, BMP6, BMPR2, and RPS19BP1, respectively).

Primer sequences are listed in Table 1. mRNA was isolated and cDNA was synthesized using the Bio-Rad RT-PCR system. First-strand synthesis was performed at 42 °C for 60 min and inactivated at 85 °C for 5 min. cDNA was used for PCR amplification in triplicate using SYBR probes on the Bio-Rad system. Amplification was carried out at 95 °C for 10 min, followed by 40 cycles at 95 °C for 10 s and 60 °C for 30 s. Quantitative values were determined from the quantification cycle (Cq), and each sample was normalized using ∆Cq.

The results were analyzed with the 2(∆∆Cq) method. Bio-Rad CFX Manager 3.1 software was used for RT-PCR data analysis.

2.11. Effects of VDR KO on Corneal Transparency and Recruitment of Immune Cells in NaOH Wounded Mice

To determine how VDR KO effects mouse corneal transparency following an alkali wound, wild-type (WT) C57BL/6J VDR KO mice (n = 5 per group) between 8 and 9 weeks old were anaesthetized with ketamine: xylazine. A central cornea injury was created by placing a 0.33 N NaOH soaked filter paper disc (2 mm diameter) on the central cornea for 10 s. Corneas were rinsed with 10 mL PBS and treated with topical antibiotic ointment 2 times per day for 3 days.

Mice were treated with buprenorphine SR as an analgesic. Mouse corneal transparency was observed and photographed up to 21 days after wounding using a Topcon slit lamp (SL-D4).

To determine the effects of VDR KO on immune cell recruitment, wounded and control mouse corneas were collected 3 weeks after NaOH wounding (n = 5 per group) and immunostained with an anti-CD45 antibody. Briefly, mouse eyes were fixed in Zamboni fixative for 75 min and washed three times with PBS (5 min each). Corneas were excised along the sclera-corneal border, rehydrated in Triton X-100/PBS, and blocked with 10% goat serum and 0.1% Triton X-100 in PBS for 60 min at room temperature.

They were then incubated with anti-CD45 antibody (1:200, Abcam) in 5% goat serum and 0.1% Triton X-100/PBS for 24 h at 4 °C with constant shaking. After three 10-min PBS washes, corneas were treated with Alexa Fluor 594 goat anti-rabbit IgG (1:1000) for 24 h at 4 °C and thoroughly washed in PBS. To image the corneas, each was flattened by making four radial cuts and mounted on a slide with the epithelium side facing up. CD45+ cell numbers were quantified using the Imaris Spots package (Oxford Instruments, Abingdon, UK).

This 3D/4D visualization software effectively counts individual cells in 2D images. By inputting a 2D image and calibrating the Spots function: selecting the average cell diameter and setting initial sensitivity: the software labels cells as spots and reports the total count. A conservative approach was used to manually adjust counts, ensuring only clear cells (spots) in saturated areas were included [40].

2.12. Statistical Analysis

Data comparisons between two groups were conducted using an unpaired Student’s t-test. One-way ANOVA with Dunnett’s multiple comparison test was used when there was more the 1 experimental group. Statistical significance was determined based on a p-value of less than 0.05. Data analysis was performed using Graph Pad Prism 10.

3. Results

3.1. Effect of Vit D on α-SMA Protein Expression in the Human Stromal Cell Line and Primary HSC Cells

TGF β1-stimulated α-SMA protein expression was significantly decreased after 72 h in the human stromal cell line and primary HSCs treated with 1,25 Vit D or 24,25 Vit D (Figure 1A: D, Supplementary Figure S1). 1,25 Vit D reduced TGF β1: stimulated α-SMA by 52.3% ± 4.1% (p < 0.001) in human stromal cells, while 24,25 Vit D reduced TGF β1: stimulated α-SMA by 48.7% ± 3.9% (p < 0.001) (Figure 1B,D). Figure 1E demonstrates decreased α-SMA immunostaining following 1,25 Vit D or 24,25 Vit D treatment in HSCs, highlighting the potential of Vit D metabolites to inhibit myofibroblast differentiation.

3.2. Effect of Vit D on α-SMA Protein Expression in Primary WT and VDR KO MSCs

TGF β1-stimulated α-SMA protein expression was decreased in cultured WT (Figure 2A,B) and VDR KO MSCs (Figure 2C,D, Supplementary Figure S2) 72 h after 1,25 Vit D or 24,25 Vit D exposure (p < 0.05). Unstimulated α-SMA protein expression was not significantly different between WT MSCs and VDR KO MSCs. Figure 2E demonstrates decreased α-SMA immunostaining following 1,25 Vit D or 24,25 Vit D treatment in MSCs.

3.3. Effect of Vit D on TGF β1-Stimulated α-SMA Protein Expression in Mouse Corneas

Cultured mouse corneas were treated with TGF β1, with or without 1,25 Vit D or 24,25 Vit D, in DMEM serum-free medium. Figure 3 (and Supplementary Figure S3) shows significantly increased α-SMA protein expression in TGF β1-treated corneas compared to controls, and decreased α-SMA protein expression in mouse corneas treated with TGF β1 plus 1,25 Vit D or 24,25 Vit D.

3.4. Effect of Vit D on Antifibrotic Protein Factor mRNA Expressional Levels in HSCs

TGF-β family members, including BMPs, are key regulators of tissue repair and fibrosis. BMP2 and BMP6 are notable antifibrotic factors, with BMP2 demonstrating the ability to inhibit fibrogenic signaling pathways and reduce collagen deposition in various tissues. Figure 4 shows qPCR results demonstrating the influence of Vit D on mRNA levels of several antifibrotic protein factors in HSCs. Results demonstrate that BMP2, 6, and BMPR2 mRNA, along with that of TGF β3, are significantly elevated by both 1,25 Vit D and 24,25 Vit D at most of the time points tested.

3.5. Effect of Vit D on BMP6 and TGF β3 Protein Expression in HSCs

Figure 5 (and Supplementary Figure S4) shows western blot data demonstrating increased HSC Vit D-stimulated protein levels of BMP6 (A,B) and TGF β3 (C,D), which were selected for protein measurement following the qPCR experiments. Treatment with 24,25 Vit D significantly increased both BMP6 and TGF-β3 protein levels compared with the control group. BMP6 expression showed an approximately 1.9 ± 0.3 fold elevation, while TGF-β3 expression increased by about 1.7 ± 0.2 fold. 1,25 Vit D also enhanced BMP6 and TGF-β3 expression, but to a slightly lesser extent. 1,25 Vit D-treated HSCs showed an approximately 1.7 ± 0.2 fold BMP6 increase, and TGF-β3 expression rose by roughly 1.6 ± 0.2 fold.

These results suggest that both active vitamin D metabolites upregulate BMP6 and TGF-β3.

3.6. Effect of VDR KO on Corneal Fibrosis

WT and VDR KO mouse corneas were injured using a 0.33N NaOH-soaked filter disc applied to the cornea for 10 s. Corneal healing/fibrosis was monitored with a slit lamp, with fluorescein staining utilized to examine epithelial healing. Epithelium of all eyes was healed by day 5; however, VDR KO mouse corneas exhibited more haze compared to WT corneas throughout the healing process. Figure 6A shows representative images of WT and VDR KO mouse corneas 14 days post-injury, with the VDR KO cornea displaying both a central epithelial defect and greater opacity. Figure 6B shows representative immunostaining for α-SMA, fibronectin, and collagen III in WT and VDR KO corneas, respectively, 14 days after alkali wounding, revealing increased expression of all three fibrotic marker proteins in the VDR KO versus WT corneas. Figure 6C shows the scoring results for each protein’s immunofluorescence.

Following wounding, WT corneas showed significantly increased α-SMA and fibronectin expression (p < 0.05) with no increase in collagen III expression. All three proteins were significantly increased in VDR KO corneas compared to unwounded WTs, with fibronectin and collagen III levels significantly increased in VDR KO compared to wounded WT corneas. The mean α-SMA score was elevated compared to wounded WTs but did not reach significance. In addition, the number of CD45+ immune cells was significantly reduced in VDR KO corneas compared to WT corneas three weeks post-wounding (Figure 7).

Specifically, wounded VDR KO corneas had 68% fewer CD45+ cells than WT post-injury (p < 0.001). This impaired immune recruitment likely potentiates fibrosis.

3.7. Localization of FAM57B in the Mouse Cornea

The FAM57B protein was recently described as a 24,25D receptor [31]. Immunohistochemical labeling of WT and KO mouse corneas revealed the presence of FAM57B in all 3 corneal cell types in both genotypes, with no discernable differences in labelling intensity (Figure 8).

4. Discussion

Vit D is well-known for its role in bone health and calcium metabolism. 1,25 Vit D is a central regulator of calcium and phosphate homeostasis and promotes cellular differentiation, stimulates apoptosis, and influences the proliferation of selected cell types. Vit D is also increasingly recognized for protective effects in head and neck tissues and cancers [54]. It modulates both innate and adaptive immunity by promoting antimicrobial peptides like cathelicidin and defensins [55]. Vitamin D also helps regulate autoimmune responses by suppressing pro-inflammatory T cells and enhancing regulatory T cells, with relevance to diseases like multiple sclerosis and rheumatoid arthritis [56].

Approximately 30 min of daily sun exposure without sunscreen is essential for the body’s natural production of vitamin D. During this process, UVB rays convert 7-dehydrocholesterol in the skin to vitamin D3, which is then hydroxylated in the liver and kidneys to form calcitriol [57].

Vitamin D plays a significant role in supporting ocular health. In the eye, vitamin D helps reduce cytokine production, oxidative stress, and microglial activation, thereby protecting against diseases such as age-related macular degeneration, dry eye syndrome, and diabetic retinopathy [14,58]. We previously determined that exposing cultured corneal epithelial cells to UV-B, in the presence of 7-dehydrocholesterol, resulted in a UV-B-dose dependent increase in vitamin D3, 1,25 Vit D and 24,25 Vit D. That same study determined that dietary vitamin D supplementation in rabbits resulted in elevated tear and anterior chamber 1,25 Vit D and 24,25 Vit D levels [58].

Vit D’s protective action is a cornerstone of numerous diseases, with Vit D deficiency-initiated oxidative stress being a significant contributor [59]. In cardiovascular tissues, VDR is expressed in fibroblasts, vascular endothelial cells, and cardiomyocytes, where vitamin D reduces renin: angiotensin system activity, enhances ACE2 expression, and lowers pro-inflammatory cytokines such as IL-1β and TNF-α [59]. Several studies have investigated the relationship between Vit D and fibrosis in different organs such as the liver, lungs, and heart [4,5,60,61].

Vit D can exert potent antifibrotic effects by attenuating NLRP3 assembly and reducing IL-1β release in both hepatic and cardiovascular tissue [59,62,63]. 1,25 Vit D was shown to prevent TGF β1-induced human cardiac fibroblast activation by inhibiting SMAD2 phosphorylation [60]. In the respiratory system, Vit D inhibits bleomycin and TGF β-induced pulmonary fibrosis [64,65]. The current study indicates that TGF β1-induced cornea myofibroblast differentiation, as determined by examining α-SMA expression, was reduced by 1,25 Vit D and 24,25 Vit D.

Importantly, it was also found that VDR KO led to more severe NaOH-induced corneal fibrosis as compared to WT mice. A more comprehensive assessment, including additional myofibroblast markers (such as fibronectin, collagen type III, and others), as well as broader transcriptional profiling, would provide a more robust evaluation of the myofibroblast differentiation process.

Wounded corneas from VDR KO mice exhibited significantly increased haze compared to those from WT mice, indicating enhanced fibrotic remodeling. Immunohistochemical analysis revealed elevated expression of key fibrotic markers in the wounded VDR KO corneas, including α-SMA, fibronectin, and collagen III. The trend of increased α-SMA expression suggests a greater presence of myofibroblasts. Similarly, increased fibronectin and collagen III deposition reflect heightened extracellular matrix production, further contributing to stromal disorganization and haze formation. These findings suggest that VDR signaling plays a critical regulatory role in limiting fibrotic responses during corneal wound healing.

Although the exact mechanisms are not fully understood, previous studies suggest that Vit D’s antifibrotic effects can be mediated by regulation of specific signaling pathways involved in fibrosis, modulation of the immune system, and its anti-inflammatory properties. Vit D metabolites may suppress TGF-β/Smad signaling. TGF β3 has been shown to be an antifibrotic agent in the cornea and several other tissues [66,67,68,69,70], possibly by upregulating SMAD7 in the cornea [71].

The current study demonstrates increased TGF β3 mRNA and protein expression in HSCs following exposure to both 1,25 Vit D and 24,25 Vit D; thus, it is possible that Vit D may reduce corneal fibrosis through the TGF β3 pathway.

Another group of TGF protein superfamily members with anti-fibrotic properties are the BMPs. A host of BMPs have been studied in the cornea, including BMP-2, -6, and -7, with each subtype being described as antifibrotic [12,13,72,73,74,75,76]. BMP-6 and BMPR2 have been reported to mediate phenotypic reversal of corneal myofibroblasts to keratocytes [77], and BMP-7 has been shown to attenuate corneal fibrosis [78,79,80].

Vit D and BMP-2 act synergistically to promote osteogenic differentiation, and PDIA3, a proposed alternative Vit D receptor, seems to be involved in this response [81,82]. The current study demonstrates increased HSC mRNA expression of BMP-2, -6, and BMPR2 (and BMP-6 protein) following 1,25 Vit D and 24,25 Vit D exposure. The influence of 24,25 Vit D on BMP signaling had not previously been reported in any cell type. The current study did not examine the possibility that the BMPs or TGF β3 were affected by TGF β1.

A separate study found that Vit D supplementation of Vit D-insufficient diabetic periodontitis patients resulted in elevated BMP-2 serum and gingival crevicular fluid samples [83]. Another study demonstrated increases of all 3 TGFβ isoforms following Vit D treatment of dermal fibroblasts [84]. In addition to BMP superfamily members, additional transcription factors and proteins that could be involved in Vit D antifibrotic activity include, but are not limited to, Snail, Slug, ZEB1, Twist, S100A4, and MYH11. To the best of our knowledge, the influence of Vit D on expression of these transcription factors and proteins has not previously been examined, and additional studies will be needed to determine how they are influenced by Vit D in the cornea.

Vitamin D upregulation of BMPs could potentially counteract TGF-β: induced fibrosis, as BMP-7 inhibits TGF β1: driven myofibroblast differentiation in renal and corneal models [85]. It would be beneficial for future studies to determine if Vit D metabolites directly modulate SMAD7 (an inhibitor of TGF-β signaling) or BMPR2 transcription.

It is well known that 1,25 Vit D works primarily through a VDR-mediated transcription mechanism in which the hormone directly regulates gene expression of a wide variety of Vit D-dependent genes in Vit D target cells. A recent study demonstrated that VDR ligands inhibit hepatic stellate cell activation and fibrosis, that VDR KO mice spontaneously develop liver fibrosis, and that VDR antagonizes SMAD3/TGF β1 activation of profibrotic genes [4]. Results of the current study determined that TGF β1-stimulated α-SMA protein expression was significantly reduced in both cultured WT and VDR KO MSCs following exposure to 1,25 Vit D or 24,25 Vit D.

Our group previously described significant physiological effects of 1,25 Vit D and 24,25 Vit D in VDR KO corneal epithelial cells, and attributed those findings to the presence of alternative Vit D receptors in these cells [32,33], and in particular the protein disulfide isomerase family member 3 (Pdia3), which has been identified as an alternative membrane-associated Vit D receptor [86]. To that end, we previously demonstrated Pdia3 expression in mouse and human corneal keratocytes [46].

Although its role beyond binding 24,25 Vit D is unexplored, we determined that a 24,25 Vit D receptor protein recently identified by St-Arnaud’s group, FAM57B2 [31], is also present in mouse corneal keratocytes as well as mouse corneal epithelial and endothelial cells. We attribute the current results observed in KO mouse MSCs to the presence of Pdia3, FAM57B2, or another alternative Vit D receptor in VDR KO MSCs. Future work could determine if FAM57B knockdown/knockout would abolish 24,25 Vit D’s antifibrotic effects.

It is important to compare results obtained from mouse and human studies, particularly when describing mouse models of human disease and developing or describing potential therapeutics. The current study found that TGF β1-induced corneal myofibroblast differentiation was significantly reduced by 1,25 Vit D and 24,25 Vit D in the human corneal stromal cell line, HSCs, MSCs, and cultured mouse corneas. These effects were confirmed in wounded mouse corneas. A previous study from our group in the corneal epithelium revealed species differences in Vit D metabolism and cell proliferation between humans and mice [46].

In cultured mouse corneal epithelium, 1,25 Vit D treatment increased CYP24A1, the enzyme responsible for inactivating 1,25 Vit D and forming 24,25 Vit D, decreased CYP27B1, the enzyme that activates Vit D, and did not affect proliferation. In human corneal epithelium, 1,25 Vit D also increased CYP24A1 expression but did not affect CYP27B1, and it reduced cell proliferation. In stromal cells of both species, 1,25 Vit D increased expression of both CYP24A1 and CYP27B1, highlighting species and cell type differences.

The differences suggest divergent metabolic regulation, impacting potential therapeutic dosing. Human corneal fibroblasts may require higher Vit D concentrations for efficacy due to catabolic differences. Topical formulations (e.g., nanocarriers) could overcome bioavailability issues [87]. A limitation of this study is that while multiple donors were used to obtain the human primary fibroblasts, the cells from individual donors were not tracked in the cell culture studies and all male donors were used. The relatively small variability in the results would indicate that there was not tremendous variability between donors.

It was surprising that the in vitro data demonstrated that both 1,25 Vit D and 24,25 Vit D suppressed α-SMA expression in TGF β1-induced stromal cells, even in the absence of VDR (indicating VDR-independent antifibrotic effects), while the in vivo results demonstrated exacerbated fibrosis in VDR KO mice after alkali injury compared to WT mice. There are several possible explanations for these seemingly contradictory results. While it might be expected that alternative receptors and endogenous 24,25 Vit D might compensate for loss of VDR in the KO mice, it is not known what concentration of 24,25D is reaching the cornea in these mice or what the density of alternative Vit D receptors might be within in vivo keratocytes.

In addition, the traditional VDR has a much higher affinity for 1,25 Vit D than other Vit D metabolites, thus it is likely that it would be difficult to overcome loss of VDR in an in vivo environment. While beyond the scope of this study, it would be interesting to determine if adding exogenous Vit D to in vivo KO mouse corneas would result in suppression of the observed fibrosis. These results also highlight the likely role of systemic and immune-mediated factors.

Specifically, the reduced infiltration of CD45+ immune cells in wounded VDR KO corneas suggests impaired immune modulation: a key regulator of fibrosis resolution that cannot be replicated in isolated cell cultures. Thus, the in vivo phenotype likely stems from compounded effects: compromised systemic immune responses due to VDR deficiency, in conjunction with cell-autonomous stromal signaling via alternative receptors like FAM57B. Future studies dissecting cell-type-specific contributions (e.g., stromal vs. immune cells) should help to further clarify these pathways.

Modulating immune responses and reducing inflammation are critical for corneal repair; for example, ocular microbiota has been found to play a role in maintaining corneal health [88]. Moreover, Vit D was found to improve wound healing and reduce IL6 production in Staphylococcus aureus-infected human keratinocytes [89]. CD45 is a marker for all hematopoietic cells except for mature erythrocytes and platelets. In the normal human and mouse cornea, there are a significant number of resident CD45+ cells within the pericentral and central region [37,90,91].

After a corneal scrape wound, neutrophils extravasate from the limbal vessels and migrate through the corneal stroma to the site of damage [92,93]. By 48 h, neutrophil levels within the stroma are near those found before injury [94]. Previous studies demonstrated that CD45+ immune cell immigration within wounded corneas occurs in two waves during the first 48 h [94]. Corneal re-epithelialization is significantly delayed in neutropenic animals, and early leukocyte emigration appears to promote re-epithelialization [95].

The current study found reduced numbers of CD45+ immune cells in VDR KO vs. WT corneas three weeks after NaOH wounding. In addition, our group recently determined that CD45+ cell numbers are reduced in diabetic and VDR KO mouse corneas compared to normoglycemic mice, and that 24,25 Vit D increased the recruitment of CD45+ cells to diabetic mouse corneas after epithelial debridement [40]. It was previously found that the VDR is required for recruitment of macrophages in cutaneous wounds, with the number of macrophages in granulation tissue markedly reduced in VDR KO compared with WT mice [96].

In addition, hepatic neutrophils are also decreased in VDR KO mice. Despite an increased awareness of the presence of corneal inflammatory cells in recent years, data demonstrating their precise role in normal corneal homeostasis is still rare [97]. Our findings suggest that Vit D and the VDR may play an important role in mitigating corneal fibrosis by modulating the immune system.

CD45+ cells have been shown to be both beneficial and detrimental as related to fibrosis. For example, CD45 cell therapy was found to be beneficial for treating CCl4-induced liver fibrosis [98], and CD45+ cells were found to alleviate bleomycin-induced pulmonary fibrosis by limiting expansion and activation of group 2 innate lymphoid cells [99]. Alternative examples include CD45+ fibrocytes promoting corneal injury-induced fibrosis [100], and CD45(+) cells correlated with mitral valve fibrosis following myocardial infarction [101].

The present study demonstrated reduced CD45+ cell infiltration following NaOH injury in VDR KO mouse corneas, which showed an enhanced fibrotic response, indicating a possible beneficial role for these cells in preventing or resolving chemical injury-induced fibrosis.

Additional limitations of the current study include an absence of VDR antagonists for validation of cell culture studies and in situ and in vivo studies that did not incorporate the VDR KO mice, limited time points and Vit D concentrations examined, and lack of in vivo functional assessments for some of the studies. It is noteworthy that we consider the 1,25 Vit D and 24,25 Vit D concentrations tested in the current study (20 nM and 100 nM, respectively) to be pharmacological doses and not physiological concentrations.

We previously determined that rabbit aqueous humor 1,25 Vit D and 24,25 Vit D levels to be as high as 0.04 nM and 0.27 nM, respectively (with no extra dietary Vit D supplementation) [58]. To the best of our knowledge, no studies have measured these Vit D metabolite concentrations in the eyes of humans or mice. We chose the higher 24,25 Vit D concentration (relative to the 1,25 Vit D concentration) due to its lower affinity for the VDR as compared to the high affinity agonist, 1,25 Vit D.

The affinity of 24,25 Vit D to the alternative receptors has not been thoroughly studied. Those Vit D concentrations examined in the current study were the same as those used in all of our previous cornea Vit D studies.

The current study indicates that 1,25 Vit D and 24,25 Vit D can be beneficial for reducing fibrotic wound healing following corneal alkali injuries. Previous work from our group demonstrated that Vit D promotes corneal epithelial wound healing. VDR KO mice have significantly slower cornea epithelial wound healing rates as compared to controls, and Vit D deficient diabetic mice have slower corneal epithelial wound healing than wild-type diabetic mice. Topical 1,25 Vit D significantly accelerated corneal epithelial wound healing in normoglycemic, diabetic, and diabetic VDD mice, and topical 24,25 Vit D significantly accelerated corneal epithelial wound healing of diabetic VDD and VDR KO mice [40].

We also found significant roles for Vit D in maintaining corneal epithelial adherens junctions, promoting gap junction communication, and affecting cell migration and proliferation. Thus, 1,25 Vit D and 24,25 Vit D appear to promote corneal wound healing following both mechanical and chemical wounding.

5. Conclusions

Our group has previously demonstrated the positive influence of Vit D on corneal epithelial cells and its involvement in corneal wound healing. The current study focused on the influence of Vit D on corneal keratocyte wound responses. We demonstrated that VDR KO resulted in increased NaOH-induced corneal fibrosis. Conversely, exposure of cultured stromal cells and mouse corneas to Vit D metabolites (1,25 Vit D and 24,25 Vit D) significantly decreased expression of α-SMA, a hallmark of myofibroblast phenotype. Furthermore, both 1,25 Vit D and 24,25 Vit D significantly increased the expression of key TGF-β superfamily antifibrotic factors BMP2, BMP6, BMPR2, and TGF-β3 at both the mRNA and protein levels in human stromal cells.

These findings highlight the robust antifibrotic potential of Vit D metabolites through modulation of critical signaling pathways. While both metabolites suppress fibrosis, 24,25 Vit D operates primarily through the newly identified receptor FAM57B (detected in all corneal layers), whereas 1,25 Vit D likely acts via VDR and PDIA3. 24,25 Vit D uniquely enhances BMP6/TGF-β3 signaling without VDR dependence, suggesting non-overlapping therapeutic targets.

Additionally, our results demonstrate that VDR plays a crucial role in immune cell recruitment during corneal wound healing. Specifically, VDR KO mouse corneas exhibited significantly reduced CD45+ immune cell infiltration following alkali injury compared to WT controls. Given the essential functions of CD45+ immune cells, including modulation of inflammation, clearance of debris and pathogens, secretion of cytokines and growth factors, and regulation of keratocyte activation, this impaired recruitment in VDR KO mice likely contributes to increased corneal fibrosis.

In summary, our findings support the beneficial role of Vit D and its receptor across multiple phases of corneal wound healing. Through the likely reduction of myofibroblast differentiation and enhancement of antifibrotic signaling through BMPs and TGF-β3 pathways, Vit D metabolites represent promising therapeutic agents for reducing corneal fibrosis after injury or surgery. The broader implications of this study along with our previous work demonstrating the beneficial effects of Vit D on corneal epithelial wound healing, including topical application of 1,25 and 24,25 Vit D, suggest potential clinical applications for topical Vit D analogs in treating ocular surface disorders characterized by fibrosis and impaired wound healing.

Although this study lacks in vivo topical or systemic Vit D treatment: an area that should be prioritized in future fibrotic wound healing research: there is strong rationale to pursue such work. Given the beneficial aspects of Vit D for many aspects of corneal wound healing and physiology, future studies should test metabolite-specific Vit D formulations (e.g., 24,25 Vit D for VDR-independent action) for their anti-fibrosis and beneficial wound healing properties following corneal injuries.

Acknowledgments

This work was supported by NIH National Eye Institute Grant EY021747 and P30 EY031631. We are grateful to Amy Estes (Department of Ophthalmology, Medical College of Georgia at Augusta University, Augusta, GA) and The Eye Guys, Eye Physicians and Surgeons of Augusta, GA for providing donor corneal rims.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cells14201583/s1, Figure S1. Western blot assay illustrating the effect of Vit D on α-SMA expression in the human stromal cell line and primary human stromal cells. Representative western blots and total protein stain-free images from (A) the human stromal cell line and (B) HSC treated with 1,25 Vit D and 24,25 Vit D. Figure S2. Western blot assay examining the effect of Vit D on a-SMA expression in MSC and VDR KO MSC.

Representative western blots and total protein stain-free images from (A) MSC and (B) VDR KO MSC treated with 1,25 Vit D and 24,25 Vit D. Figure S3. Western blot results and total protein stain-free image examining the effect of Vit D on a-SMA protein expression in mouse corneas treated with 1,25 Vit D and 24,25 Vit D. Figure S4. Representative western blots and total protein stain-free images demonstrating the effects of 1,25 Vit D and 24,25 Vit D on HSC (A) BMP6 and (B) TGF β3 protein expression (n = 3).

Supplement file at the original source: open the original paper. This file is not included in this text import.

Author Contributions

X.L. performed experiments, analyzed data, and wrote the manuscript, including figure preparation. Z.C. and J.L. performed experiments, analyzed data, and edited the manuscript. M.A.W. designed the study, analyzed data, and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

The animal study protocol was approved by the Augusta University Institutional Animal Care and Use Committee (protocol code 2013-0581 and date of approval on 16 August 2022).

Informed Consent Statement

Not applicable.

Data Availability Statement

Any data not contained within the manuscript will be available on request.

Conflicts of Interest

The authors declare no conflicts of interest.

References

1. Whitcher J.P. Srinivasan M. Upadhyay M.P. Corneal blindness: A global perspective Bull. World Health Organ. 2001 79 214 221 11285665 PMC2566379
2. Wilson S.E. Sampaio L.P. Shiju T.M. Hilgert G.S.L. de Oliveira R.C. Corneal Opacity: Cell Biological Determinants of the Transition From Transparency to Transient Haze to Scarring Fibrosis, and Resolution, After Injury Investig. Ophthalmol. Vis. Sci. 2022 63 22 10.1167/iovs.63.1.22 PMC8787546 35044454
3. Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system Biochim. Biophys. Acta 2011 1814 186 199 10.1016/j.bbapap.2010.06.022 20619365
4. Ding N. Yu R.T. Subramaniam N. Sherman M.H. Wilson C. Rao R. Leblanc M. Coulter S. He M. Scott C. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response Cell 2013 153 601 613 10.1016/j.cell.2013.03.028 23622244 PMC3673534
5. Guijarro T. Magro-Lopez E. Manso J. Garcia-Martinez R. Fernandez-Acenero M.J. Liste I. Zambrano A. Detrimental pro-senescence effects of vitamin D on lung fibrosis Mol. Med. 2018 24 64 10.1186/s10020-018-0064-z 30567504 PMC6299997
6. Hah N. Sherman M.H. Yu R.T. Downes M. Evans R.M. Targeting Transcriptional and Epigenetic Reprogramming in Stromal Cells in Fibrosis and Cancer Cold Spring Harb. Symp. Quant. Biol. 2015 80 249 255 10.1101/sqb.2015.80.027185 26801159
7. Sriram G. Bigliardi P.L. Bigliardi-Qi M. Fibroblast heterogeneity and its implications for engineering organotypic skin models in vitro Eur. J. Cell Biol. 2015 94 483 512 10.1016/j.ejcb.2015.08.001 26344860
8. Jia S. Chen F. Wang H. Kesavamoorthy G. Lai J.S. Wong I.Y. Chiu K. Chan J.C. Effect of Vitamin D3 on Regulating Human Tenon’s Fibroblasts Activity Transl. Vis. Sci. Technol. 2021 10 7 10.1167/tvst.10.8.7 PMC8287040 34251424
9. Wilson S.E. Mohan R.R. Mohan R.R. Ambrosio R. Jr. Hong J. Lee J. The corneal wound healing response: Cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells Prog. Retin. Eye Res. 2001 20 625 637 10.1016/S1350-9462(01)00008-8 11470453
10. Watsky M.A. Weber K.T. Sun Y. Postlethwaite A. New insights into the mechanism of fibroblast to myofibroblast transformation and associated pathologies Int. Rev. Cell Mol. Biol. 2010 282 165 192 10.1016/S1937-6448(10)82004-0 20630469
11. Wilson S.E. Corneal myofibroblasts and fibrosis Exp. Eye Res. 2020 201 108272 10.1016/j.exer.2020.108272 33010289 PMC7736212
12. Mohan R.R. Kim W.J. Mohan R.R. Chen L. Wilson S.E. Bone morphogenic proteins 2 and 4 and their receptors in the adult human cornea Investig. Ophthalmol. Vis. Sci. 1998 39 2626 2636 9856772
13. Kim W.J. Mohan R.R. Mohan R.R. Wilson S.E. Effect of PDGF, IL-1alpha, and BMP2/4 on corneal fibroblast chemotaxis: Expression of the platelet-derived growth factor system in the cornea Investig. Ophthalmol. Vis. Sci. 1999 40 1364 1372 10359318
14. Reins R.Y. McDermott A.M. Vitamin D: Implications for ocular disease and therapeutic potential Exp. Eye Res. 2015 134 101 110 10.1016/j.exer.2015.02.019 25724179 PMC4426046
15. Mutti D.O. Marks A.R. Blood levels of vitamin D in teens and young adults with myopia Optom. Vis. Sci. 2011 88 377 382 10.1097/OPX.0b013e31820b0385 21258262 PMC3044787
16. Millen A.E. Voland R. Sondel S.A. Parekh N. Horst R.L. Wallace R.B. Hageman G.S. Chappell R. Blodi B.A. Klein M.L. Vitamin D status and early age-related macular degeneration in postmenopausal women Arch. Ophthalmol. 2011 129 481 489 10.1001/archophthalmol.2011.48 21482873 PMC3075411
17. Graffe A. Milea D. Annweiler C. Beauchet O. Mauget-Faysse M. Beauchet O. Kodjikian L. Milea D. Association between hypovitaminosis D and late stages of age-related macular degeneration: A case-control study J. Am. Geriatr. Soc. 2012 60 1367 1369 10.1111/j.1532-5415.2012.04015.x 22788394
18. Payne J.F. Ray R. Watson D.G. Delille C. Rimler E. Cleveland J. Lynn M.J. Tangpricha V. Srivastava S.K. Vitamin D insufficiency in diabetic retinopathy Endocr. Pract. 2012 18 185 193 10.4158/EP11147.OR 21940279 PMC4706181
19. Orton S.M. Morris A.P. Herrera B.M. Ramagopalan S.V. Lincoln M.R. Chao M.J. Vieth R. Sadovnick A.D. Ebers G.C. Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis Am. J. Clin. Nutr. 2008 88 441 447 10.1093/ajcn/88.2.441 18689381 PMC2740974
20. Yoo T.K. Oh E. Hong S. Is vitamin D status associated with open-angle glaucoma? A cross-sectional study from South Korea Public Health Nutr. 2014 17 833 843 10.1017/S1368980013003492 24476947 PMC10282225
21. de Haan J.B. Bladier C. Griffiths P. Kelner M. O’Shea R.D. Cheung N.S. Bronson R.T. Silvestro M.J. Wild S. Zheng S.S. Mice with a homozygous null mutation for the most abundant glutathione peroxidase, Gpx1, show increased susceptibility to the oxidative stress-inducing agents paraquat and hydrogen peroxide J. Biol. Chem. 1998 273 22528 22536 10.1074/jbc.273.35.22528 9712879
22. Shokravi M.T. Marcus D.M. Alroy J. Egan K. Saornil M.A. Albert D.M. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma Investig. Ophthalmol. Vis. Sci. 1995 36 83 87 7529753
23. Suzuki T. Sano Y. Kinoshita S. Effects of 1alpha,25-dihydroxyvitamin D3 on Langerhans cell migration and corneal neovascularization in mice Investig. Ophthalmol. Vis. Sci. 2000 41 154 158 10634615
24. Albert D.M. Scheef E.A. Wang S. Mehraein F. Darjatmoko S.R. Sorenson C.M. Sheibani N. Calcitriol is a potent inhibitor of retinal neovascularization Investig. Ophthalmol. Vis. Sci. 2007 48 2327 2334 10.1167/iovs.06-1210 17460298
25. Tang J. Zhou R. Luger D. Zhu W. Silver P.B. Grajewski R.S. Su S.B. Chan C.C. Adorini L. Caspi R.R. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response J. Immunol. 2009 182 4624 4632 10.4049/jimmunol.0801543 19342637 PMC2756755
26. Lee V. Rekhi E. Hoh Kam J. Jeffery G. Vitamin D rejuvenates aging eyes by reducing inflammation, clearing amyloid beta and improving visual function Neurobiol. Aging 2012 33 2382 2389 10.1016/j.neurobiolaging.2011.12.002 22217419
27. Kutuzova G.D. Gabelt B.T. Kiland J.A. Hennes-Beann E.A. Kaufman P.L. DeLuca H.F. 1alpha,25-Dihydroxyvitamin D(3) and its analog, 2-methylene-19-nor-(20S)-1alpha,25-dihydroxyvitamin D(3) (2MD), suppress intraocular pressure in non-human primates Arch. Biochem. Biophys. 2012 518 53 60 10.1016/j.abb.2011.10.022 22198282 PMC3390938
28. Bikle D.D. Vitamin D: A calciotropic hormone regulating calcium-induced keratinocyte differentiation J. Am. Acad. Dermatol. 1997 37 S42 S52 9344184
29. Boyan B.D. Wong K.L. Fang M. Schwartz Z. 1alpha,25(OH)2D3 is an autocrine regulator of extracellular matrix turnover and growth factor release via ERp60 activated matrix vesicle metalloproteinases J. Steroid Biochem. Mol. Biol. 2007 103 467 472 10.1016/j.jsbmb.2006.11.003 17224270 PMC2754708
30. Lee S.A. Yang H.W. Um J.Y. Shin J.M. Park I.H. Lee H.M. Vitamin D attenuates myofibroblast differentiation and extracellular matrix accumulation in nasal polyp-derived fibroblasts through smad2/3 signaling pathway Sci. Rep. 2017 7 7299 10.1038/s41598-017-07561-6 28779150 PMC5544725
31. Lu X. Watsky M.A. Influence of Vitamin D on Corneal Epithelial Cell Desmosomes and Hemidesmosomes Investig. Ophthalmol. Vis. Sci. 2019 60 4074 4083 10.1167/iovs.19-27796 31561249 PMC6779066
32. Yin Z. Pintea V. Lin Y. Hammock B.D. Watsky M.A. Vitamin D enhances corneal epithelial barrier function Investig. Ophthalmol. Vis. Sci. 2011 52 7359 7364 10.1167/iovs.11-7605 21715350 PMC3183972
33. Martineau C. Naja R.P. Husseini A. Hamade B. Kaufmann M. Akhouayri O. Arabian A. Jones G. St-Arnaud R. Optimal bone fracture repair requires 24R,25-dihydroxyvitamin D3 and its effector molecule FAM57B2 J. Clin. Investig. 2018 128 3546 3557 10.1172/JCI98093 30010626 PMC6063485
34. Lu X. Chen Z. Mylarapu N. Watsky M.A. Effects of 1,25 and 24,25 Vitamin D on Corneal Epithelial Proliferation, Migration and Vitamin D Metabolizing and Catabolizing Enzymes Sci. Rep. 2017 7 16951 10.1038/s41598-017-16698-3 29208972 PMC5717139
35. Liu J. Li Z. Resident Innate Immune Cells in the Cornea Front. Immunol. 2021 12 620284 10.3389/fimmu.2021.620284 33717118 PMC7953153
36. Wu M. Hill L.J. Downie L.E. Chinnery H.R. Neuroimmune crosstalk in the cornea: The role of immune cells in corneal nerve maintenance during homeostasis and inflammation Prog. Retin. Eye Res. 2022 91 101105 10.1016/j.preteyeres.2022.101105 35868985
37. Wilson S.E. Sampaio L.P. Shiju T.M. de Oliveira R.C. Fibroblastic and bone marrow-derived cellularity in the corneal stroma Exp. Eye Res. 2021 202 108303 10.1016/j.exer.2020.108303 33068626 PMC7855915
38. Brissette-Storkus C.S. Reynolds S.M. Lepisto A.J. Hendricks R.L. Identification of a novel macrophage population in the normal mouse corneal stroma Investig. Ophthalmol. Vis. Sci. 2002 43 2264 2271 12091426 PMC3253392
39. Lassance L. Marino G.K. Medeiros C.S. Thangavadivel S. Wilson S.E. Fibrocyte migration, differentiation and apoptosis during the corneal wound healing response to injury Exp. Eye Res. 2018 170 177 187 10.1016/j.exer.2018.02.018 29481786 PMC5924631
40. Chinnery H.R. McMenamin P.G. Dando S.J. Macrophage physiology in the eye Pflugers Arch. 2017 469 501 515 10.1007/s00424-017-1947-5 28233124
41. Lu X. Chen Z. Lu J. Watsky M.A. Effects of Topical 1,25 and 24,25 Vitamin D on Diabetic, Vitamin D Deficient and Vitamin D Receptor Knockout Mouse Corneal Wound Healing Biomolecules 2023 13 1065 10.3390/biom13071065 37509101 PMC10377579
42. Mangusho G. Njogu E. Baingana R.K. David-Kigaru D.M. Vitamin A-related nutrition knowledge gaps and predictors among caregivers of preschool children in Eastern Uganda: A cross-sectional study BMC Nutr. 2024 10 85 10.1186/s40795-024-00891-5 38863006 PMC11167797
43. Morelli-Batters A. Lamont H.C. Elghobashy M. Masood I. Hill L.J. The role of Vitamin D3 in ocular fibrosis and its therapeutic potential for the glaucomatous trabecular meshwork Front. Ophthalmol. 2022 2 897118 10.3389/fopht.2022.897118 PMC11182265 38983544
44. Artaza J.N. Norris K.C. Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells J. Endocrinol. 2009 200 207 221 10.1677/JOE-08-0241 19036760 PMC3787314
45. Griffith M. Osborne R. Munger R. Xiong X. Doillon C.J. Laycock N.L. Hakim M. Song Y. Watsky M.A. Functional human corneal equivalents constructed from cell lines Science 1999 286 2169 2172 10.1126/science.286.5447.2169 10591651
46. Doillon C.J. Watsky M.A. Hakim M. Wang J. Munger R. Laycock N. Osborne R. Griffith M. A collagen-based scaffold for a tissue engineered human cornea: Physical and physiological properties Int. J. Artif. Organs 2003 26 764 773 10.1177/039139880302600810 14521175
47. Lu X. Chen Z. Watsky M.A. Effects of 1,25 and 24,25 Vitamin D on Corneal Fibroblast VDR and Vitamin D Metabolizing and Catabolizing Enzymes Curr. Eye Res. 2021 46 1271 1282 10.1080/02713683.2021.1884726 33535006 PMC8363511
48. Funderburgh J.L. Mann M.M. Funderburgh M.L. Keratocyte phenotype mediates proteoglycan structure: A role for fibroblasts in corneal fibrosis J. Biol. Chem. 2003 278 45629 45637 10.1074/jbc.M303292200 12933807 PMC2877919
49. Pei Y. Sherry D.M. McDermott A.M. Thy-1 distinguishes human corneal fibroblasts and myofibroblasts from keratocytes Exp. Eye Res. 2004 79 705 712 10.1016/j.exer.2004.08.002 15500828
50. Hu X. Du S. Yu J. Yang X. Yang C. Zhou D. Wang Q. Qin S. Yan X. He L. Common housekeeping proteins are upregulated in colorectal adenocarcinoma and hepatocellular carcinoma, making the total protein a better “housekeeper” Oncotarget 2016 7 66679 66688 10.18632/oncotarget.11439 27556505 PMC5341829
51. Gilda J.E. Ghosh R. Cheah J.X. West T.M. Bodine S.C. Gomes A.V. Western Blotting Inaccuracies with Unverified Antibodies: Need for a Western Blotting Minimal Reporting Standard (WBMRS) PLoS ONE 2015 10 e0135392 10.1371/journal.pone.0135392 26287535 PMC4545415
52. Kejner A.E. Burch M.B. Sweeny L. Rosenthal E.L. Bone Morphogenetic Protein 6 Expression in Oral Cavity Squamous Cell Cancer is Associated With Bone Invasion Laryngoscope 2013 123 3061 3065 10.1002/lary.24267 23775772 PMC3805669
53. Mohsin S.K. Weiss H. Havighurst T. Clark G.M. Berardo M. Roanh L.D. To T.V. Qian Z. Love R.R. Allred D.C. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study Mod. Pathol. 2004 17 1545 1554 10.1038/modpathol.3800229 15272277
54. Brust L.A. Linxweiler M. Schnatmann J. Kuhn J.P. Knebel M. Braun F.L. Wemmert S. Menger M.D. Schick B. Holick M.F. Effects of Vitamin D on tumor cell proliferation and migration, tumor initiation and anti-tumor immune response in head and neck squamous cell carcinomas Biomed. Pharmacother. 2024 180 117497 10.1016/j.biopha.2024.117497 39341078 PMC12959379
55. Aranow C. Vitamin D and the immune system J. Investig. Med. 2011 59 881 886 10.2310/JIM.0b013e31821b8755 PMC3166406 21527855
56. Dankers W. Colin E.M. van Hamburg J.P. Lubberts E. Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential Front. Immunol. 2016 7 697 10.3389/fimmu.2016.00697 28163705 PMC5247472
57. Holick M.F. Vitamin D deficiency N. Engl. J. Med. 2007 357 266 281 10.1056/NEJMra070553 17634462
58. Lin Y. Ubels J.L. Schotanus M.P. Yin Z. Pintea V. Hammock B.D. Watsky M.A. Enhancement of vitamin D metabolites in the eye following vitamin D3 supplementation and UV-B irradiation Curr. Eye Res. 2012 37 871 878 10.3109/02713683.2012.688235 22632164 PMC3572765
59. Dentino P. Mora J. Zuo L. Vitamin D Deficiency and Its Role in Pathologies of Oxidative Stress: A Literature Review Cureus 2025 17 e90042 10.7759/cureus.90042 40951130 PMC12432480
60. Meredith A. Boroomand S. Carthy J. Luo Z. McManus B. 1,25 Dihydroxyvitamin D3 Inhibits TGFbeta1-Mediated Primary Human Cardiac Myofibroblast Activation PLoS ONE 2015 10 e0128655 10.1371/journal.pone.0128655 26061181 PMC4462580
61. Voisin T. Joannes A. Morzadec C. Lagadic-Gossmann D. Naoures C.L. De Latour B.R. Rouze S. Jouneau S. Vernhet L. Antifibrotic effects of vitamin D3 on human lung fibroblasts derived from patients with idiopathic pulmonary fibrosis J. Nutr. Biochem. 2024 125 109558 10.1016/j.jnutbio.2023.109558 38185349
62. Karakasis P. Pamporis K. Theofilis P. Milaras N. Vlachakis P.K. Grigoriou K. Patoulias D. Karamitsos T. Antoniadis A.P. Fragakis N. Inflammasome Signaling in Cardiac Arrhythmias: Linking Inflammation, Fibrosis, and Electrical Remodeling Int. J. Mol. Sci. 2025 26 5954 10.3390/ijms26135954 40649732 PMC12249723
63. Ma W. Wang Y. Liu J. NLRP3 Inflammasome Activation in Liver Disorders: From Molecular Pathways to Therapeutic Strategies J. Inflamm. Res. 2025 18 8277 8294 10.2147/JIR.S532908 40585040 PMC12205705
64. Zhang Z. Yu X. Fang X. Liang A. Yu Z. Gu P. Zeng Y. He J. Zhu H. Li S. Preventive effects of vitamin D treatment on bleomycin-induced pulmonary fibrosis Sci. Rep. 2015 5 17638 10.1038/srep17638 26627341 PMC4667265
65. Ramirez A.M. Wongtrakool C. Welch T. Steinmeyer A. Zugel U. Roman J. Vitamin D inhibition of pro-fibrotic effects of transforming growth factor beta1 in lung fibroblasts and epithelial cells J. Steroid Biochem. Mol. Biol. 2010 118 142 150 10.1016/j.jsbmb.2009.11.004 19931390 PMC2821704
66. Karamichos D. Hutcheon A.E. Zieske J.D. Reversal of fibrosis by TGF-beta3 in a 3D in vitro model Exp. Eye Res. 2014 124 31 36 10.1016/j.exer.2014.04.020 24800655 PMC4065812
67. Carrington L.M. Albon J. Anderson I. Kamma C. Boulton M. Differential regulation of key stages in early corneal wound healing by TGF-beta isoforms and their inhibitors Investig. Ophthalmol. Vis. Sci. 2006 47 1886 1894 10.1167/iovs.05-0635 16638995
68. Ask K. Bonniaud P. Maass K. Eickelberg O. Margetts P.J. Warburton D. Groffen J. Gauldie J. Kolb M. Progressive pulmonary fibrosis is mediated by TGF-beta isoform 1 but not TGF-beta3 Int. J. Biochem. Cell Biol. 2008 40 484 495 10.1016/j.biocel.2007.08.016 17931953 PMC2350199
69. Hosokawa R. Nonaka K. Morifuji M. Shum L. Ohishi M. TGF-beta 3 decreases type I collagen and scarring after labioplasty J. Dent. Res. 2003 82 558 564 10.1177/154405910308200714 12821719
70. Occleston N.L. Laverty H.G. O’Kane S. Ferguson M.W. Prevention and reduction of scarring in the skin by Transforming Growth Factor beta 3 (TGFbeta3): From laboratory discovery to clinical pharmaceutical J. Biomater. Sci. Polym. Ed. 2008 19 1047 1063 10.1163/156856208784909345 18644230
71. Guo X. Hutcheon A.E.K. Zieske J.D. Molecular insights on the effect of TGF-beta1/-beta3 in human corneal fibroblasts Exp. Eye Res. 2016 146 233 241 10.1016/j.exer.2016.03.011 26992778 PMC4893894
72. Chung Y.H. Huang Y.H. Chu T.H. Chen C.L. Lin P.R. Huang S.C. Wu D.C. Huang C.C. Hu T.H. Kao Y.H. BMP-2 restoration aids in recovery from liver fibrosis by attenuating TGF-beta1 signaling Lab. Investig. 2018 98 999 1013 10.1038/s41374-018-0069-9 29789683
73. Wall N.A. Blessing M. Wright C.V. Hogan B.L. Biosynthesis and in vivo localization of the decapentaplegic-Vg-related protein, DVR-6 (bone morphogenetic protein-6) J. Cell Biol. 1993 120 493 502 10.1083/jcb.120.2.493 8421061 PMC2119526
74. Yang Y.L. Liu Y.S. Chuang L.Y. Guh J.Y. Lee T.C. Liao T.N. Hung M.Y. Chiang T.A. Bone morphogenetic protein-2 antagonizes renal interstitial fibrosis by promoting catabolism of type I transforming growth factor-beta receptors Endocrinology 2009 150 727 740 10.1210/en.2008-0090 18832104
75. Zeisberg M. Hanai J. Sugimoto H. Mammoto T. Charytan D. Strutz F. Kalluri R. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury Nat. Med. 2003 9 964 968 10.1038/nm888 12808448
76. Zhong L. Wang X. Wang S. Yang L. Gao H. Yang C. The anti-fibrotic effect of bone morphogenic protein-7(BMP-7) on liver fibrosis Int. J. Med. Sci. 2013 10 441 450 10.7150/ijms.5765 23471555 PMC3590605
77. Zhu Y.T. Li F. Zhang Y. Chen S.Y. Tighe S. Lin S.Y. Tseng S.C.G. HC-HA/PTX3 Purified From Human Amniotic Membrane Reverts Human Corneal Fibroblasts and Myofibroblasts to Keratocytes by Activating BMP Signaling Investig. Ophthalmol. Vis. Sci. 2020 61 62 10.1167/iovs.61.5.62 32462202 PMC7405802
78. Saika S. Ikeda K. Yamanaka O. Flanders K.C. Nakajima Y. Miyamoto T. Ohnishi Y. Kao W.W. Muragaki Y. Ooshima A. Therapeutic effects of adenoviral gene transfer of bone morphogenic protein-7 on a corneal alkali injury model in mice Lab. Investig. 2005 85 474 486 10.1038/labinvest.3700247 15696184
79. Tandon A. Sharma A. Rodier J.T. Klibanov A.M. Rieger F.G. Mohan R.R. BMP7 gene transfer via gold nanoparticles into stroma inhibits corneal fibrosis in vivo PLoS ONE 2013 8 e66434 10.1371/journal.pone.0066434 23799103 PMC3682981
80. Lim R.R. Tan A. Liu Y.C. Barathi V.A. Mohan R.R. Mehta J.S. Chaurasia S.S. ITF2357 transactivates Id3 and regulate TGFbeta/BMP7 signaling pathways to attenuate corneal fibrosis Sci. Rep. 2016 6 20841 10.1038/srep20841 26865052 PMC4750002
81. Song I. Kim B.S. Kim C.S. Im G.I. Effects of BMP-2 and vitamin D3 on the osteogenic differentiation of adipose stem cells Biochem. Biophys. Res. Commun. 2011 408 126 131 10.1016/j.bbrc.2011.03.135 21463608
82. Chen J.X. Dosier C.R. Park J.H. De S. Guldberg R.E. Boyan B.D. Schwartz Z. Mineralization of three-dimensional osteoblast cultures is enhanced by the interaction of 1α,25-dihydroxyvitamin D3 and BMP2 via two specific vitamin D receptors J. Tissue Eng. Regen. Med. 2016 10 40 51 10.1002/term.1770 23784946
83. Lei F. Ni J. Hu J.L. Guo D.N. Fan J. Different doses of vitamin D supplementation to nonsurgical treatment for vitamin-D-insufficient patients with diabetic periodontitis and the effect on gingival BMP-2 levels Kaohsiung J. Med. Sci. 2023 39 1030 1037 10.1002/kjm2.12726 37395326 PMC11895881
84. Oyama N. Iwatsuki K. Satoh M. Akiba H. Kaneko F. Dermal fibroblasts are one of the therapeutic targets for topical application of 1alpha,25-dihydroxyvitamin D3: The possible involvement of transforming growth factor-beta induction Br. J. Dermatol. 2000 143 1140 1148 10.1046/j.1365-2133.2000.03880.x 11122013
85. Li Y.J. Spataro B.C. Yang J.W. Dai C.S. Liu Y.H. 1,25-dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression Kidney Int. 2005 68 1500 1510 10.1111/j.1523-1755.2005.00562.x 16164627
86. Nemere I. Farach-Carson M.C. Rohe B. Sterling T.M. Norman A.W. Boyan B.D. Safford S.E. Ribozyme knockdown functionally links a 1,25(OH)2D3 membrane binding protein (1,25D3-MARRS) and phosphate uptake in intestinal cells Proc. Natl. Acad. Sci. USA 2004 101 7392 7397 10.1073/pnas.0402207101 15123837 PMC409929
87. Smith E.M. Tangpricha V. Driving up the Dose: Implications for High-Dose Vitamin D Therapy Endocr. Pract. 2015 21 1178 1180 10.4158/EP15899.CO 26439002 PMC4824637
88. St Leger A.J. Desai J.V. Drummond R.A. Kugadas A. Almaghrabi F. Silver P. Raychaudhuri K. Gadjeva M. Iwakura Y. Lionakis M.S. An Ocular Commensal Protects against Corneal Infection by Driving an Interleukin-17 Response from Mucosal gammadelta T Cells Immunity 2017 47 148 158.e145 10.1016/j.immuni.2017.06.014 28709803 PMC5553552
89. Zanetta P. Ballacchino C. Squarzanti D.F. Amoruso A. Pane M. Azzimonti B. Lactobacillus johnsonii LJO02 (DSM 33828) Cell-Free Supernatant and Vitamin D Improve Wound Healing and Reduce Interleukin-6 Production in Staphylococcus aureus-Infected Human Keratinocytes Pharmaceutics 2023 16 18 10.3390/pharmaceutics16010018 38276496 PMC10820395
90. Mayer D.J. Daar A.S. Casey T.A. Fabre J.W. Localization of Hla-a, Hla-B, Hla-C and Hla-Dr Antigens in the Human Cornea: Practical Significance for Grafting Technique and Hla Typing Transplant. Proc. 1983 15 126 129
91. Williams K.A. Ash J.K. Coster D.J. Histocompatibility antigen and passenger cell content of normal and diseased human cornea Transplantation 1985 39 265 269 10.1097/00007890-198503000-00011 3156436
92. Hanlon S.D. Smith C.W. Sauter M.N. Burns A.R. Integrin-dependent neutrophil migration in the injured mouse cornea Exp. Eye Res. 2014 120 61 70 10.1016/j.exer.2014.01.004 24462632 PMC3970182
93. Scapini P. Lapinet-Vera J.A. Gasperini S. Calzetti F. Bazzoni F. Cassatella M.A. The neutrophil as a cellular source of chemokines Immunol. Rev. 2000 177 195 203 10.1034/j.1600-065X.2000.17706.x 11138776
94. Li Z. Burns A.R. Smith C.W. Two waves of neutrophil emigration in response to corneal epithelial abrasion: Distinct adhesion molecule requirements Investig. Ophthalmol. Vis. Sci. 2006 47 1947 1955 10.1167/iovs.05-1193 16639002
95. Zhang W. Magadi S. Li Z. Smith C.W. Burns A.R. IL-20 promotes epithelial healing of the injured mouse cornea Exp. Eye Res. 2017 154 22 29 10.1016/j.exer.2016.11.006 27818315 PMC5359042
96. Song L. Papaioannou G. Zhao H. Luderer H.F. Miller C. Dall’Osso C. Nazarian R.M. Wagers A.J. Demay M.B. The Vitamin D Receptor Regulates Tissue Resident Macrophage Response to Injury Endocrinology 2016 157 4066 4075 10.1210/en.2016-1474 27526034 PMC5045513
97. Oh J.Y. Choi H. Lee R.H. Roddy G.W. Ylostalo J.H. Wawrousek E. Prockop D.J. Identification of the HSPB4/TLR2/NF-kappaB axis in macrophage as a therapeutic target for sterile inflammation of the cornea EMBO Mol. Med. 2012 4 435 448 10.1002/emmm.201200221 22359280 PMC3403300
98. Baligar P. Mukherjee S. Kochat V. Rastogi A. Mukhopadhyay A. Molecular and Cellular Functions Distinguish Superior Therapeutic Efficiency of Bone Marrow CD45 Cells Over Mesenchymal Stem Cells in Liver Cirrhosis Stem Cells 2016 34 135 147 10.1002/stem.2210 26389810
99. Cui G. Shimba A. Jin J. Hojo N. Asahi T. Abe S. Ejima A. Okada S. Ohira K. Kato R. CD45 alleviates airway inflammation and lung fibrosis by limiting expansion and activation of ILC2s Proc. Natl. Acad. Sci. USA 2023 120 e2215941120 10.1073/pnas.2215941120 37639581 PMC10483638
100. de Oliveira R.C. Wilson S.E. Fibrocytes, Wound Healing, and Corneal Fibrosis Investig. Ophthalmol. Vis. Sci. 2020 61 28 10.1167/iovs.61.2.28 32084275 PMC7326569
101. Bischoff J. Casanovas G. Wylie-Sears J. Kim D.H. Bartko P.E. Guerrero J.L. Dal-Bianco J.P. Beaudoin J. Garcia M.L. Sullivan S.M. CD45 Expression in Mitral Valve Endothelial Cells After Myocardial Infarction Circ. Res. 2016 119 1215 1225 10.1161/CIRCRESAHA.116.309598 27750208 PMC5215059
Figure 1

Western blot assay and immunostaining illustrating the effect of Vit D on α-SMA expression in the human stromal cell line and primary human stromal cells. Representative western blots from (A) the human stromal cell line and (C) HSCs treated with 1,25 Vit D and 24,25 Vit D. Corresponding average blot density graphs with total protein normalization from (B) the human stromal cell line and (D) HSCs treated with 1,25 Vit D and 24,25 Vit D. (E) Representative immunofluorescence labelling examining the effect of Vit D on α-SMA (green) expression in HSCs with representative secondary antibody negative control (n = 5, Mean ± SE. * p < 0.05; DAPI (blue)).

Individual data points superimposed on bar graphs. Western blot original images are shown in Supplementary Materials Figure S1.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 2

Western blot assay examining the effect of Vit D on α-SMA expression in MSCs and VDR KO MSCs. Representative western blots from (A) MSCs and (C) VDR KO MSCs treated with 1,25 Vit D and 24,25 Vit D. Corresponding average blot density graphs with total protein normalization from (B) MSCs and (D) VDR KO MSCs treated with 1,25 Vit D and 24,25 Vit D. (E) Representative immunofluorescence labelling examining the effect of Vit D on α-SMA expression (green) in MSCs with representative secondary antibody negative control (n = 5, Mean ± SE. * p < 0.05; DAPI (blue)).

Western blot original images are shown in the Supplementary Materials Figure S2.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 3

Western blot results examining the effect of Vit D on α-SMA protein expression in mouse corneal tissue. (A) Representative western blots from mouse corneal tissue treated with 1,25 Vit D and 24,25 Vit D. (B) Corresponding average blot density graph, normalized to total protein, of mouse corneal tissue treated with 1,25 Vit D and 24,25 Vit D (n = 5, Mean ± SE. * p < 0.05). Individual data points superimposed on bar graphs. Western blot original images are shown in the Supplementary Materials Figure S3.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 4

HSCs qPCR results for BMP2, BMP6, BMP2R, and TGFβ3 at indicted time points following 1,25D and 24,25D exposure. * p < 0.05 compared to DMSO vehicle, n = 3.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 5

Representative western blots with accompanying density plots (relative %) demonstrating the effects of 1,25 Vit D and 24,25 Vit D on HSC (A,B) BMP6 and (C,D) TGF β3 protein expression; * p < 0.05 by unpaired t-test. Dots represent individual data points. Western blot original images are shown in the Supplementary Materials Figure S5.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 6

(A) Representative slit lamp images showing the effects of alkali wounding (0.33N NaOH) on WT, VDR KO corneas 10 days after wounding along with an unwounded WT cornea. (B) Representative α-SMA (magenta), fibronectin (orange), and collagen III (green) protein expression in WT and VDR KO mice 14 days after NaOH wounding along with an unwounded WT cornea and secondary antibody negative controls (DAPI-blue). (C) Blinded scoring of protein expression levels of the proteins and groups represented in (B).

Data are presented as mean ± SEM; * p < 0.05 by unpaired t-test. Dots represent individual data points.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 7

CD45 immunostaining (green) of NaOH wounded (0.33N) (A) WT and (B) VDR KO mouse corneas 3 weeks after wounding. (C) Secondary antibody negative control. DAPI staining in blue. (D) CD45+ cell count in WT and VDR KO corneas with individual data points superimposed. * p < 0.05.

Figure image at the original source: open the original paper. This file is not included in this text import.
Figure 8

FAM57B immunostaining (green) in mouse corneas. (A,B) WT corneas with and without DAPI staining (blue). (C,D) KO corneas with and without DAPI staining. (E,F) Secondary antibody negative control WT corneas with and without DAPI staining. Abbreviations: Ep-epithelium, Ke-keratocytes, En-endothelium.

Figure image at the original source: open the original paper. This file is not included in this text import.
Table 1

Summary of primer pair sets.

GeneDirectionPrimer SequenceProduct Size (bp)Melting
Temperature
Homo sapiens TGFβ3 Forward5′-AAGAAGCGGGCTTTGGAC-3′6260 °C
Reverse5′-CGCACACAGCAGTTCTCC-3′
Homo sapiens BMP2 Forward5′-CCCAGCGTGAAAAGAGAGAC-3′16861 °C
Reverse5′-GAGACCGCAGTCCGTCTAAG-3′
Homo sapiens BMP6 Forward5′-AGCGACACCACAAAGAGTTCA-3′15962 °C
Reverse5′-GCTGATGCTCCTGTAAGACTTGA-3′
Homo sapiens RPS19BP1Forward5′-CGTGGCTGAGTCTGTGAGC-3′12060 °C
Reverse5′-GTCTTCCTCGGTGAACACG-3′
Homo sapiens BMPRForward5′-CTTTACTGAGAATTTTCCACCTCCTG-3′9059 °C
Reverse5′-GCCAAAGCAATGATTAT TGTCTCATC-3′
Publication and source details

Original title: Suppression of Cornea Stromal Fibrosis by Vitamin D

Xiaowen Lu; Zhong Chen; Jerry Lu; Mitchell A. Watsky

Cells · 2025

* Correspondence: mwatsky@augusta.edu; Tel.: +1-(706)-721-3278; Fax: +1-(706)-721-6829© 2025 by the authors.2025https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).NIH National Eye InstituteR01EY021747P30 EY031631This work was supported by NIH National Eye Institute grants R01EY021747 and P30 EY031631.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:59:50.561957+00:00

DOI: 10.3390/cells14201583 · PMC12562390